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Abstract 
 
Human immunodeficiency virus (HIV), the causative agent of the acquired 
immunodeficiency syndrome (AIDS), remains a topic of global concern even though great 
strides have been made to combat the virus. The high replicative rate of the virus and 
recombination of the variety of viral strains complicate the treatment of AIDS. There has 
been an increasing prevalence of African HIV strains in the Americas and Europe. The viral 
protease (PR) is vital for the propagation of the virus; and thus, is a major target in antiviral 
therapy. The HIV-1 PR enzyme from the subtype C strain; which predominates in sub-
Saharan Africa, has been greatly under-investigated in comparison to the protease from the 
subtype B strain which predominates in North America and Europe. Enzyme activity data 
which were part of this work suggested that the South African HIV-1 subtype C protease (C-
SA PR) displays improved substrate turnover in comparison to the subtype B PR. 
Thermodynamics and inhibition kinetics of drug binding showed that the C-SA PR is less 
susceptible to certain clinically-used protease inhibitors when compared to the subtype B PR. 
A crystal structure of the C-SA PR was solved and showed no difference to the global 
structure of the subtype B PR. Molecular dynamics simulations showed that the C-SA PR 
exhibits a wider range of open conformations. Hydrogen/deuterium exchange-mass 
spectrometry (HDX-MS) was performed to elucidate the mechanism of reduced drug 
susceptibility displayed by the C-SA PR. HDX-MS data provided insights into the basis of 
the increased preference for open conformers displayed by the C-SA PR and the stability of 
the terminal dimer interface which is a target in protease inhibition. 
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Non-B HIV-1 Subtypes in sub-Saharan Africa: Impact of 
Subtype on Protease Inhibitor Efficacy 
 
Previn Naicker and Yasien Sayed.  
 
Biol. Chem., In Press. (2014). 
 
 
In this publication, a detailed introduction into HIV is given. Information on the genetic 
diversity of HIV type 1 and characteristics of the HIV-1 subtype C is presented. Comparisons 
between the subtype B and C proteases are made and the secondary resistance mutations 
inherent to the C-SA PR are discussed. An account of some novel anti-HIV drugs is also 
provided.  
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 Review 
 Previn  Naicker and  Yasien  Sayed * 
 Non-B HIV-1 subtypes in sub-Saharan Africa: 
impact of subtype on protease inhibitor efficacy 
 Abstract:  In 2012, 25 million people [71% of global human 
immunodeficiency virus (HIV) infection] were estimated 
to be living with HIV in sub-Saharan Africa. Of these, 
approximately 1.6 million were new infections and 1.2 
million deaths occurred. South Africa alone accounted for 
31% of HIV/acquired immunodeficiency syndrome (AIDS) 
deaths in sub-Saharan Africa. This disturbing statistic 
indicates that South Africa remains the epicenter of the 
HIV/AIDS pandemic, compounded by the fact that only 
36% of HIV-positive patients in South Africa have access to 
antiretroviral (ARV) treatment. Drug resistance mutations 
have emerged, and current ARVs show reduced efficacy 
against non-B subtypes. In addition, several recent stud-
ies have shown an increased prevalence of non-B African 
HIV strains in the Americas and Europe. Therefore, the 
use of ARVs in a non-B HIV-1 subtype context requires fur-
ther investigation. HIV-1 subtype C protease, found largely 
in sub-Saharan Africa, has been under-investigated when 
compared with the subtype B protease, which predomi-
nates in North America and Europe. This review, there-
fore, focuses on HIV-1 proteases from B and C subtypes. 
 Keywords:  African subtypes;  AIDS;  drug resistance;  novel 
protease inhibitors. 
 DOI 10.1515/hsz-2014-0162 
 Received  March  5 ,  2014 ; accepted  May  12 ,  2014 
 Introduction 
 Acquired immunodeficiency syndrome (AIDS) has caused 
major global health and socioeconomic challenges over 
the past three decades. Human immunodeficiency virus 
(HIV), the causative agent of AIDS, has been extensively 
investigated in research laboratories throughout the 
world. Genotypic characterization of the virus and antiret-
roviral (ARV) drug development efforts have been exhaus-
tive and are ongoing. Understanding the virus at the 
molecular level is a basic requirement, and the knowledge 
gained from these studies would help drive drug develop-
ment. Globally, there are roughly 35 million people living 
with HIV and 71% reside in sub-Saharan Africa ( The Joint 
Nations Program on HIV/AIDS, 2013 ). Statistics on ARV 
efficacy during long-term treatment are generally poor. 
Statistics from sub-Saharan countries are especially poor 
due to the cost of HIV monitoring and various socioeco-
nomic challenges. This is an unfortunate reality because 
reports of drug resistance as well as the genetic variation 
of HIV are on the rise ( Rousseau et al., 2007 ;  Shafer and 
Schapiro, 2008 ;  Hemelaar et al., 2011 ). 
 HIV is a retrovirus. The survival of the virus in a 
human host requires the viral genetic material (RNA) 
to be reverse transcribed to DNA by the viral reverse 
transcriptase (RT). Owing to the RT enzyme lacking 
proofreading ability and the high replication rate of 
HIV, mutations occur frequently in the viral proteins 
that are targeted by antiviral drugs, thereby providing a 
challenge for the production of effective antiviral com-
pounds. Currently, there are six classes of anti-HIV drugs 
( Table 1 ): nucleoside RT inhibitors (NRTIs), non-nucleo-
side RT inhibitors (NNRTIs), protease inhibitors (PIs), 
integrase inhibitors, fusion inhibitors, and entry inhibi-
tors. RT and PIs are recommended in treatment regimens 
globally, and extensive data are available on the drug-
resistance profiles of these therapeutics ( World Health 
Organization, 2013 ). Fewer information is available on 
the newer classes of inhibitors and reduced efficacies 
due to drug-resistance mutations (DRMs) are inevitable. 
Efforts to produce an effective HIV vaccine are ongoing 
( Moore et al., 2012 ), and the control of HIV epidemiology 
in the interim is reliant on RT and PIs. Importantly, more 
mutations are selected in response to PIs than any other 
class of ARV ( Shafer and Schapiro, 2008 ). In this review, 
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we focus on the subtype C protease (PR) prevalent in 
sub-Saharan Africa with special attention to the South 
African HIV-1 subtype C PR. Approximately 12% of the 
South African population are HIV positive (6.1 million 
out of a total population of 52 million people) ( The Joint 
Nations Program on HIV/AIDS, 2013 ). This alarming sta-
tistic reflects that South Africa is the epicenter of the HIV/
AIDS pandemic. Although there are excellent reviews 
on HIV-1 subtype B and non-B subtypes ( Kantor and 
Katzenstein, 2003 ;  Martinez-Cajas et al., 2009 ;  Wainberg 
and Brenner, 2010 ), there are very few reviews on PRs 
from sub-Saharan Africa ( Bessong, 2008 ). Therefore, a 
clear understanding of the role of genetic diversity and 
subtype variation and their impact on viral fitness and 
drug efficacy must be addressed. 
 Genetic diversity of HIV 
 Two types of HIV have been identified: HIV-1 and HIV-2. 
HIV-1 is the predominant type and is separated into 
groups M, N, O, and P ( Taylor et al., 2008 ;  Plantier et al., 
2009 ). Group M (comprising 95% of the complete genome 
sequences of HIV-1) is further separated into nine subtypes 
(A, B, C, D, F, G, H, J, and K) and a growing number of cir-
culating recombinant forms (CRFs) as shown in  Figure 1 
( Taylor et  al., 2008 ). A recombinant strain is defined as 
a CRF if it has been fully sequenced and isolated in three 
or more epidemiologically distinct individuals ( Robertson 
et al., 2000 ). Currently, recombinants are estimated to con-
tribute to a minimum of 20% of the global HIV-1 infections 
( Hemelaar et al., 2011 ). Unique recombinant forms (URFs) 
 Table 1   FDA-approved ARV drugs for treatment of HIV infection. 
Generic name   Manufacturer   Approval date 
NRTIs
   Zidovudine, AZT   GlaxoSmithKline   March 19, 1987
   Didanosine, dideoxyinosine (ddl)   Bristol Myers-Squibb   October 9, 1991
   Zalcitabine, dideoxycytidine (ddC) (no longer marketed)   Hoffmann-La Roche   June 19, 1992
   Stavudine (d4T)   Bristol Myers-Squibb   June 24, 1994
   Lamivudine (3TC)   GlaxoSmithKline   November 17, 1995
   Abacavir sulfate   GlaxoSmithKline   December 17, 1998
   Tenofovir disoproxil fumarate (TDF)   Gilead Sciences   October 26, 2001
   Emtricitabine (FTC)   Gilead Sciences   July 02, 2003
NNRTIs
   Nevirapine (NVP)   Boehringer Ingelheim   June 21, 1996
   Delavirdine (DLV)   Pfizer   April 4, 1997
   Efavirenz (EFV)   Bristol Myers-Squibb   September 17, 1998
   Etravirine   Tibotec Therapeutics   January 18, 2008
   Rilpivirine   Tibotec Therapeutics   May 20, 2011
Pis
   Saquinavir mesylate (SQV)   Hoffmann-La Roche   December 6, 1995
   Ritonavir (RTV)   Abbott Laboratories   March 1, 1996
   Indinavir (IDV)   Merck   March 13, 1996
   Nelfinavir mesylate (NFV)   Agouron Pharmaceuticals   March 14, 1997
   Amprenavir (APV) (no longer marketed)   GlaxoSmithKline   April 15, 1999
   Lopinavir (LPV)   Abbott Laboratories   September 15, 2000
   Atazanavir sulfate (ATV)   Bristol-Myers Squibb   June 20, 2003
   Fosamprenavir calcium (FOS-APV)   GlaxoSmithKline   October 20, 2003
   Tipranavir (TPV)   Boehringer Ingelheim   June 22, 2005
   Darunavir (DRV)   Tibotec   June 23, 2006
Fusion inhibitors
   Enfuvirtide (T-20)   Hoffmann-La Roche and Trimeris  March 13, 2003
Entry inhibitors (CCR5 co-receptor antagonist)
   Maraviroc   Pfizer   August 06, 2007
HIV integrase strand transfer inhibitors
   Raltegravir   Merck   October 12, 2007
   Dolutegravir   GlaxoSmithKline   Auguste 13, 2013 
 List excludes approved inhibitors that are combined or modified. 
 Adapted from the U.S. Food and Drug Administration,  http://www.fda.gov/ForConsumers/byAudience/For Patient Advocates/HIVandAIDS-
Activities/ucm118915.htm. 
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 Figure 1   Groups of HIV-1. 
 The nine subtypes of the major group are displayed. There have 
been reports of 61 CRFs in HIV-1 group M to date (Los Alamos HIV 
sequence database,  http://www.hiv.lanl.gov/content/sequences/
HIV/CRFs/CRFs.html ). 
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refer to strains that do not satisfy the aforementioned cri-
teria ( Robertson et al., 2000 ). The extension designated to 
a CRF indicates the subtype from which the CRF is derived 
( Hemelaar, 2012 ). If the CRF consists of contributions from 
more than two subtypes, it bears a  ‘ cpx ’ (complex) exten-
sion ( Hemelaar, 2012 ). Recombination events have been 
reported between different strains from different HIV-1 
groups (M and O) as well as within and between group 
M subtypes ( Rousseau et  al., 2007 ). Importantly, intra-
subtype recombination has been established as being 
widespread within group M, subtype C HIV-1 ( Rousseau 
et al., 2007 ). Recombination events are ongoing in many 
countries worldwide, where different CRFs and subtypes 
co-circulate ( Hemelaar, 2012 ). A high prevalence of URFs 
is observed in West Africa, and the CRFs involved include 
CRF02, CRF06_cpx, and CRF09_cpx ( Delgado et al., 2008 ). 
Some CRFs have recombined even further with other CRFs 
or subtypes, resulting in second-generation recombinants 
(SGRs) ( Hemelaar, 2012 ). 
 HIV-1 subtype C is the most common subtype world-
wide and occurs mainly in sub-Saharan Africa, India, 
Brazil, and China, and these regions are most heavily 
afflicted by HIV and AIDS ( Hemelaar et al., 2011 ). Studies 
have been performed on the interaction of PIs with PRs of 
subtype B HIV origin, which occurs mainly in regions of 
North America and Europe ( Hemelaar et al., 2011 ). More 
recently, studies have emerged on the efficacy of ARVs 
against viral proteins of non-B HIV-1 subtypes ( Velazquez-
Campoy et  al., 2003 ;  Mosebi et  al., 2008 ;  Ahmed et  al., 
2013 ). Interestingly, the proportion of non-B subtypes in 
the Americas and Europe is on the rise, especially those 
subtypes that predominate in Africa ( Descamps et  al., 
2005 ;  Holguin et  al., 2008 ;  Kanizsai et  al., 2010 ;  Foster 
et al., 2014 ;  Mendoza et al., 2014 ). Therefore, the sustain-
ability and future efficacy of ARVs in clinical use today are 
a concern. 
 HIV-1 subtype C 
 Subtype C viruses account for approximately 50% of 
HIV-1 infections worldwide ( Hemelaar et  al., 2011 ). The 
increased prevalence of this subtype in the Western world 
and its dominance in sub-Saharan Africa and India pose 
vital questions on the approach of current drug develop-
ment strategies and the efficacy of long-term use of ARVs. 
Irrespective of the subtype, efficient processing of Gag 
and Gag-Pol polyproteins is required for viral propaga-
tion ( Kaplan et al., 1993 ). In total, there are 12 HIV-1 cleav-
age sites in the Gag, Gag-Pol, and nef precursor proteins 
( Figure 2 ) ( de Oliveira et al., 2003 ). The majority of these 
sites are significantly more diverse in subtype C viruses 
when compared with subtype B viruses ( de Oliveira et al., 
2003 ). Natural variation at cleavage sites in subtype C 
viruses may be involved in disease progression, response 
to therapy, and regulation of the viral cycle ( de Oliveira 
et al., 2003 ). The disproportionate increase in the preva-
lence of the subtype C strain in comparison to other HIV-1 
viruses implies that subtype C HIV-1 may have a greater 
level of viral fitness at the population level or may be 
more easily transmitted ( Bessong, 2008 ). These intriguing 
details warrant further investigation into the structural 
and functional features of the subtype C PR and a com-
parison to the well-investigated subtype B PR. 
 Comparison of viral fitness between 
subtype B and C proteases 
 Mature dimeric PR is released from the Gag-Pol polypro-
tein during precursor processing ( Kaplan et  al., 1993 ). 
Production of mature PR appears to be catalyzed by 
the Gag-Pol precursor itself ( Pettit et al., 2005 ). It is still 
unclear whether the initial cleavage is accomplished 
intra- or inter-molecularly ( Wiegers et  al., 1998 ;  Pettit 
et al., 2005 ). The active site of the PR is formed at the dimer 
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interface by the enzymatic residues (D25/D25 ′ ) shown in 
 Figure 3 . Aberrant virions that are significantly less infec-
tive may appear due to defects in the PR activity ( Kaplan 
et al., 1993 ;  Wiegers et al., 1998 ;  Huang and Chen, 2010 ). 
Such defects include mutations that modify the order of 
cleavage or the rate of processing or that result in incor-
rect cleavage at any site ( Kaplan et al., 1993 ;  Wiegers et al., 
1998 ;  Huang and Chen, 2010 ). Therefore, the PR remains a 
major target of anti-HIV drug development and one of the 
most well-studied enzymes by researchers in academia 
and industry. This is evidenced by the development of 10 
U.S. Food and Drug Administration (FDA)-approved PIs 
from December 1995 to June 2006 ( Table 1 ). 
 The PDB is replete with HIV PR structures, many of 
which, however, are redundant. Thus far, the majority 
of PR crystal structures in the PDB are representative of 
HIV-1 subtype B, and only four crystal structures of HIV-1 
subtype C PR have been solved. We recently published the 
first crystal structure of the South African HIV-1 subtype C 
PR ( Naicker et al., 2013a,b ). Interestingly, even within HIV 
subtypes, genetic diversity occurs due to the error-prone 
nature of the virus as well as mutations resulting from 
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Protease cleavage sites in HIV-1
Gag-Pol (Pr160)
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6
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PR RT RNase H IN
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12
 Figure 2   HIV-1 PR cleavage sites within Gag, Gag-Pol, and nef proteins. 
 Proteins released following cleavage of Gag and Gag-Pol are matrix (MA), capsid (CA), nucleocapsid (NC), p2, p1, transframe protein (TFP), 
p6 gag , p6 pol , PR, RT, RNase H, and integrase (IN) (de Oliveira et al., 2003). 
 Figure 3   Cartoon representation of the HIV-1 PR. 
 Spheres represent positions of the polymorphic sites that exist between subtype B and C-SA PRs. Active site residues (D25) shown as 
sticks. Sequence alignment below shows differences between the PRs at the level of primary structure. PDB ID: 3U71 ( Naicker et al., 
2013a,b ). 
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environmental factors and drug pressure ( Taylor et  al., 
2008 ;  Hemelaar et al., 2011 ). The consensus sequence of 
the HIV-1 subtype C PR occurring in South Africa (C-SA 
PR) shares the same sequence identity as the consen-
sus subtype C PR in group M (Los Alamos HIV sequence 
database,  http://www.hiv.lanl.gov/ ). It is anticipated that 
approximately 15% – 20% of adults in South Africa will 
experience virologic failure within the first 2 years of treat-
ment with the first-line ARV regimen ( Coetzee et al., 2004 ). 
Therefore, there is still a dependency on the second-
line regimen comprising RT inhibitors and PIs in South 
Africa. The C-SA PR differs from the consensus subtype B 
PR at eight positions in each monomer (Los Alamos HIV 
sequence database,  http://www.hiv.lanl.gov/ ) shown in 
 Figure 3 . The polymorphisms occur distal to the active site 
and mutations at these sites do not affect drug binding/
substrate cleavage directly. 
 From among the plethora of biochemical techniques 
available, isothermal titration calorimetry represents 
the most powerful and versatile method to evaluate the 
thermodynamics and binding affinity of a drug toward 
its target in a single experiment. Thermodynamic analy-
ses of interactions between the PR and FDA-approved PIs 
indicate that the C-SA PR, generally, displays reduced sus-
ceptibility to PIs ( Velazquez-Campoy et al., 2003 ;  Mosebi 
et al., 2008 ) and that binding affinities of PIs were 3- to 
24-fold weaker for the C-SA PR than for the subtype B PR 
( Velazquez-Campoy et  al., 2003 ). Amprenavir, indinavir, 
nelfinavir, and saquinavir displayed 3- to 6-fold weaker 
binding, whereas lopinavir and ritonavir displayed sig-
nificant reductions in affinity with 8- to 24-fold weaker 
binding ( Velazquez-Campoy et al., 2003 ). The calculated 
binding affinity of PIs measured during a 2-ns molecular 
dynamics (MD) simulation showed a general reduction of 
0.5 – 2 kcal/mol in binding energy for the C-SA PR relative 
to the subtype B PR ( Ahmed et al., 2013 ). Apart from the 
genetic variability observed between B and C-PRs, pheno-
typic assays revealed that IC 90 values for subtype C HIV-1 
strains were 0.16- to 3-fold greater than the control subtype 
B strain in the presence of indinavir, nelfinavir, ritonavir, 
and saquinavir ( Shafer et al., 1999 ). These results suggest 
that subtype C HIV-1 may have improved viral fitness 
and marginally reduced drug susceptibility to most FDA-
approved PIs in comparison to the subtype B HIV-1. 
 Clinical data from ARV treatment programs in sub-
Saharan Africa reveal that drug-resistance patterns are 
similar between B and non-B HIV-1 subtypes ( Barth et al., 
2010 ). Interestingly, naturally occurring polymorphisms 
in strains such as subtype C HIV-1 have an additive effect 
on resistance mutations ( Velazquez-Campoy et al., 2002 ). 
Only few studies have directly compared the clinical 
outcome of ARV treatments among patients harboring dif-
ferent subtypes ( Del Amo et al., 1998 ;  Alaeus et al., 1999 ; 
 Alexander et  al., 2002 ;  Pillay et  al., 2002 ). Owing to the 
large diversity of HIV strains globally, clinical studies 
compare disease progression in individuals infected with 
varying HIV subtypes; however, these studies have not 
directly compared individuals infected with either subtype 
B or subtype C HIV-1 alone. However, in drug-experienced 
HIV-infected individuals, there is a strong correlation 
between unfavorable virologic response to ritonavir/
saquinavir treatments and mutations at protease posi-
tions 10, 36, and 93 ( Harrigan et al., 1999 ;  Zolopa et al., 
1999 ). Positions 36 and 93 are natural polymorphic sites in 
the C-SA PR. In contrast, studies of patients infected with 
B or non-B HIV-1 strains in Canada ( Alexander et al., 2002 ) 
and Europe ( Del Amo et  al., 1998 ;  Alaeus et  al., 1999 ; 
 Pillay et al., 2002 ) revealed no association between HIV-1 
subtype and disease progression. These findings may 
indeed be complicated by patients infected with multiple 
HIV-1 strains and disparity in treatment regimens. 
 A recent structural and computational study indi-
cated that the differences drug efficacy may be explained 
by key differences at the hinge region of the PR comprising 
amino acids at residue positions 35 – 42 and 57 – 61 ( Naicker 
et al., 2013a,b ). The stability of the hinge region of the PR 
influences the movement of the closely associated flaps 
comprising amino acids at residue positions 46 – 54. The 
flaps shield the PR-active site (seen above the active site 
in  Figure 3 ), and therefore, flap opening is required for 
substrate/inhibitor entry into the active site. Increased 
flap flexibility is associated with weaker interactions with 
inhibitors. MD simulation results showed that although 
the extent of flap opening of both the C-SA and subtype B 
PRs are similar, the inter-flap distance measured showed 
greater fluctuation for the C-SA PR for the majority of the 
10-ns simulation ( Naicker et  al., 2013a,b ). Thus, C-SA 
PR flaps sample a larger range of conformations, which 
implies greater flexibility around the flap tips. Because 
the flap regions of both PRs are identical, the mecha-
nism of increased flexibility may not be straightforward. 
Detailed structural analysis of the apo-forms of the C-SA 
and subtype B PRs showed that increased flexibility of the 
flap region may be due to subtle differences in the hinge 
region ( Naicker et al., 2013a,b ). The difference is due to the 
absence of the E35-R57 salt bridge in the C-SA PR. In the 
subtype B PR, M36 most likely facilitates formation of the 
salt bridge, whereas, I36 in the C-SA PR does not facilitate 
the formation of the salt bridge. The E35-R57 ionic inter-
action is the only salt bridge in the flap-hinge region of 
the PR and may be a key requirement for maintaining the 
rigidity of the hinge region. Therefore, polymorphisms at 
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position 36 are likely to increase flexibility of the flap tips, 
which is clearly evident in the C-SA PR crystal structure 
and MD simulations ( Naicker et al., 2013a,b ). 
 Secondary resistance mutations 
in HIV-1 subtype C PR 
 Secondary resistance mutations occur distal to the active 
site and are not implicated by themselves in high-level 
drug resistance ( Rose et  al., 1996 ;  Nijhuis et  al., 1999 ). 
They either contribute to drug resistance in the presence 
of selected primary resistance mutations or upregulate 
PR activity to compensate for the reduction in catalytic 
efficiency caused by the selected primary PR resistance 
mutations ( Rose et al., 1996 ;  Nijhuis et al., 1999 ). Certain 
secondary resistance mutations (e.g., M36I) may also 
increase the genetic barrier, thereby enhancing the 
emergence of primary resistance mutations ( Perno et al., 
2004 ). Both D30N and L90M primary DRMs occur in 
non-B viruses during nelfinavir therapy. However, D30N 
occurs more commonly in subtype B viruses, whereas 
L90M occurs more frequently in subtype C, F, G, and CRF 
01_AE viruses ( Cane et  al., 2001 ;  Abecasis et  al., 2005 ). 
Importantly, the increased preference for certain subtypes 
to develop L90M may be associated with the occurrence 
of residues other than leucine (subtype B consensus) at 
position 89 (e.g., methionine in subtype C) ( Cane et  al., 
2001 ;  Abecasis et  al., 2005 ;  Shafer and Schapiro, 2008 ). 
The residue at position 90 is situated on the  α -helix of 
the terminal domain, which interacts with the surface 
of the hydrophobic core domain and L90M may disrupt 
the packing of the two domains ( Rose et  al., 1998 ). The 
same mutation often occurs in response to inhibitors of 
entirely different chemical scaffolds. Therefore, these 
drug-resistant mutations are conserved and suggest a 
mechanism of drug resistance independent of the inhibi-
tor used ( Rose et al., 1998 ). T47S is another polymorphism 
that is linked to reduced susceptibility toward nelfinavir 
and occurs in approximately 8% of subtype C viruses, but 
rarely in other subtypes ( Rhee et al., 2006 ). These findings 
suggest that subtype C viruses are more prone to develop 
drug resistance to PIs than subtype B viruses. 
 Specific mutations (e.g., V82I) within the PR have 
been found to play a greater role in drug resistance. The 
occurrence of such mutations appears to differ between 
subtypes ( Kantor and Katzenstein, 2003 ). The V82I 
mutation occurs in approximately 1% of untreated HIV-1 
subtype B-infected individuals. Interestingly, this muta-
tion has been observed in 6% and 9% of subtype C- and 
subtype F-infected individuals, respectively, and is the 
consensus ( > 50%) in untreated subtype G-infected indi-
viduals ( Kantor and Katzenstein, 2003 ). In South Africa, 
as in other European countries ( Pereira-Vaz et al., 2009 ), 
amino acid insertions are now being detected more fre-
quently in the PR hinge region in treatment-na ï ve HIV-1 
subtype C patients ( Bessong et  al., 2006 ;  Pereira-Vaz 
et  al., 2009 ). With improving HIV surveillance in Africa 
and India, it is expected that more of these HIV-1 variants 
will be detected. The exact role of insertions have not been 
elucidated, however, they may be implicated in improving 
viral fitness by increasing the catalytic efficiency of the PR 
( Kozisek et al., 2008 ). Inhibition data suggest that inser-
tions in the hinge region contribute to PI resistance only 
in combination with other mutations in the PR or Gag and 
Gag-Pol ( Kozisek et al., 2008 ). 
 Novel strategies for overcoming 
drug resistance and future 
directions 
 All currently available PIs are active site inhibitors. 
Efforts are currently underway to design more adaptable 
PIs that will adjust to slight structural changes due to 
resistance mutations. New alternative classes of PIs may 
provide a higher barrier to resistance and improve HIV 
PR selectivity. Improved drug selectivity may help reduce 
side effects associated with antiviral therapy (e.g., lypo-
dystrophy syndrome, hyperlipidemia, diarrhea). One such 
alternative is dimerization inhibitors. HIV PR is an obli-
gate homodimer, and disruption of dimer formation leads 
to inactivation of the PR ( Hansen et al., 1988 ). The termi-
nal dimer interface (residue positions 1 – 5 and 95 – 99) is 
conserved across all HIV subtypes, and resistance muta-
tions at these sites are not likely to develop. Disruption 
of a few key interactions at the terminal dimer interface 
has been shown to eliminate the formation of a PR dimer 
( Choudhury et al., 2003 ;  Pettit et al., 2003 ;  Naicker et al., 
2013a,b ). Mutation of the ultimate amino acid, F99, to an 
alanine resulted in the formation of two monomers with 
the concomitant loss in enzyme activity ( Naicker et  al., 
2013a,b ). Experimental dimerization inhibitors showed 
reduced potency relative to their clinically available 
active site inhibitor counterparts ( Babe et al., 1992 ). Slight 
improvements of dimerization inhibitors are required to 
make them clinically effective, especially when consider-
ing they have a high barrier to resistance and may display 
reduced side effects. 
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 Improved pharmacological features such as drug 
absorption and half-life are always important consid-
erations during drug development. Recent investigations 
with our collaborators has led to the discovery and syn-
thesis of novel transition-state analogues, pentacycloun-
decane (PCU) cage-incorporated peptides, with anti-HIV 
PR activity ( Makatini et  al., 2011 ;  Karpoormath et  al., 
2013 ;  Makatini et  al., 2013 ). The lipophilic nature of the 
cage compounds confers excellent chemical properties 
required for drug delivery. Cage compounds covalently 
linked to pharmaceutically active molecules have been 
shown to reduce drug biodegradation, thereby increas-
ing the half-life of the drug ( Ito et  al., 2007 ). The bulky 
hydrocarbon scaffold aids in the transport of the drugs 
across cellular membranes ( Ito et  al., 2007 ). The PCU-
incorporated compound (PCU-lactam-EAIS) with the 
greatest potency (IC 50 = 0.078  μ m ) serves as a template for 
compounds with higher efficacy ( Makatini et  al., 2011 ). 
The coupling of the PCU-lactam ( Figure 4 A) to a variety of 
peptide side chains showed minimal effect on the inhibi-
tory potential ( Makatini et al., 2011 ). Removal of the cage 
resulted in a complete loss of inhibitory activity ( Makatini 
et al., 2011 ). Therefore, the cage lactam is the key compo-
nent for inhibition. PCU-peptides showed between 6000 
and 8000 times less toxicity to human MT-4 cells than 
lopinavir ( Makatini et  al., 2011 ), further enhancing the 
potential of these novel PIs. 
 Other novel PIs currently under development and 
that are being tested against the C-SA PR include linear 
and cyclic glycopeptides incorporating a hydroxy propyl 
amine as a transition-state analogue ( Pawar et al., 2013 ). 
Nuclear magnetic resonance studies have shown that the 
sugar moiety induces a turn in the linear peptides and 
shows a good correlation with the corresponding cyclic 
peptides ( Pawar et  al., 2013 ). The hydroxy propyl amine 
forms hydrogen bonds with the enzymatic residues (D25/
D25 ′ ) of the PR, showing great potential as a transition-
state analogue. Another exciting development is the for-
mulation of dual-action HIV-1 PR/RT inhibitors ( Figure 
4 B). Coumarin moieties conjugated to the RT inhibitor 
azidothymidine (AZT) have shown promise as dual-action 
inhibitors ( Olomola et al., 2013 ). The AZT moiety showed 
complete inhibitory potency, whereas the coumarin 
derivative exhibited moderate inhibition of the PR (two 
to four times weaker inhibition than ritonavir) ( Olomola 
et  al., 2013 ). The  N -benzylated coumarin-AZT analogues 
displayed great promise, with the  N -benzyl group enhanc-
ing the RT inhibition activity. These compounds were iso-
lated in high yields, which ranged between 70% and 80% 
( Olomola et al., 2013 ), further validating the potential of 
these compounds as novel dual-action inhibitors. 
 ARV interventions that are effective against a variety 
of HIV subtypes and drug-resistant strains are focus 
areas in HIV/AIDS research at present. Overcoming drug 
resistance is not limited to the development of novel PIs. 
Additionally, the production of an effective HIV vaccine 
is the aspiration of many researchers, particularly a 
vaccine that confers immunity to HIV-1 strains from sub-
Saharan Africa. Efforts to stimulate production of broadly 
cross-neutralizing (BCN) antibodies through vaccination 
have been largely unsuccessful ( Haynes and Montefiori, 
2006 ;  Hu and Stamatatos, 2007 ). A minority of individu-
als develop antibodies naturally after several years post 
infection ( Stamatatos et al., 2009 ). Little is known about 
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how these specific neutralizing antibodies arise. However, 
recent encouraging strides have been made that enhance 
our understanding of BCN antibodies ( Moore et al., 2012 ). 
Glycans are known to play an important role in shielding 
neutralizing epitopes on the HIV envelope and thus viral 
escape. BCN responses have been shown to directly target 
these glycans including one at position 332 in the immu-
nogenic C3 region of the gp120 subunit of the HIV-1 enve-
lope protein ( Walker et al., 2011 ;  Moore et al., 2012 ). 
 Importantly, in HIV-1 subtype C viruses, the absence 
of the 332 glycan is favored at transmission ( Moore et al., 
2012 ). Absence of the 332 glycan confers resistance to 
Asn332-dependent BCN monoclonal antibodies ( Walker 
et  al., 2011 ). Shortly after transmission, immune pres-
sure by strain-specific neutralizing antibodies triggers the 
evolution of the 332 glycan ( Moore et al., 2012 ). The evo-
lution of such epitopes provide vital targets for neutrali-
zation of subtype C viruses. Two patients from a cohort 
of 79 subtype C HIV-1-infected women developed Asn332-
dependent BCN antibodies ( Moore et al., 2012 ). The glycan 
that formed the core of the BCN epitope was absent on the 
infecting virus for both patients but evolved shortly there-
after ( Moore et al., 2012 ). Using clones of the acute virus 
and a 6-month representative virus of both patients, novel 
BCN epitopes were identified. The transfer of a glycan from 
position 334 to 332 allowed the virus to escape autologous 
neutralizing antibodies; however, this created a new BCN 
epitope that provided the antigenic stimulus to produce 
BCN antibodies targeting the 332 glycan ( Moore et  al., 
2012 ). A glycan at position 160, which was initially absent 
was also shown to emerge in patients after 3 – 6 months of 
transmission with HIV-1 ( Moore et al., 2012 ). Interestingly, 
BCN antibodies develop more frequently in infected indi-
viduals for those targeting epitopes directed toward the 
160 or 332 glycans rather than the membrane-proximal 
region or CD4 binding site ( Walker et al., 2010 ;  Tomaras 
et  al., 2011 ). These useful insights are of great value for 
the production of effective HIV vaccines, especially those 
conferring immunity to subtype C HIV-1. 
 Great advances are being made to elucidate the 
mechanisms behind the reduced drug efficacy associ-
ated with subtype variation. A number of drug develop-
ment strategies to improve PIs are being explored. The 
C-SA PR remains an epidemiologically relevant protein 
to investigate, and further structural and dynamic analy-
ses of this enzyme may reveal key insights for future drug 
development. 
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CHAPTER 2 
General introduction 
2.1 Overview 
 
Human immunodeficiency virus (HIV) continues to be one of the most problematic 
pathogens. HIV infection progresses to Acquired Immunodeficiency Syndrome (AIDS) 
resulting in severe suppression of the immune system in infected individuals. The latest 
statistics on world-wide HIV infection shows approximately 35 million people were living 
with HIV in 2012
1
. Therefore, HIV remains a serious pandemic that occurs predominantly in 
sub-Saharan Africa (approximately 25 million living with HIV); with 1.6 million new 
infections occurring in 2012
1
. Producing effective drugs against HIV has been an uphill battle 
since it was first isolated in 1983 by Barre-Sinoussi and co-workers
2
. This difficulty is due 
mainly to the viral reverse transcriptase (RT), which is prone to introducing mutations into 
the genes of the virus
3
. RT is responsible for transcribing the viral RNA to DNA that 
integrates into the host cell’s genome3. Owing to the mutation-prone nature of RT and the 
high replication rate of HIV, alterations and mutations are incorporated rapidly in viral 
proteins which antiviral drugs target; thereby, providing a challenge for the production of 
effective antivirals
3
. One such protein is the HIV protease (PR) which cleaves immature viral 
polyproteins into mature and functional proteins for the production of infective virions
4
. HIV 
PR targets a total of 12 cleavage sites in the Gag and Gag-pol polyproteins and the HIV nef 
protein
5
. Thus, PR has been identified as a major target in HIV therapy
4; 6
. The life cycle of 
HIV is depicted in Figure 1. 
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 Figure 1: HIV life cycle. Stages of the life cycle are numbered. 1: Binding of HIV to 
receptors on the surface of the CD4
+
 T-lymphocyte and fusion with the host cell. 2: Reverse 
transcription of single-stranded viral RNA to double-stranded viral DNA. 3: Entry of viral 
DNA into the nucleus of the host cell. 4: Integration of the viral DNA into the host cell’s 
DNA. 5: Transcription of viral mRNA from the HIV genomic material. 6: Assembly of newly 
translated viral enzymes, structural proteins, and RNA. 7: Budding of the assembled virion 
from the host cell. 8: Release of the HIV virion into the surrounding environment. 9: 
Maturation of HIV into its infective form. The HIV protease cleaves viral proteins into their 
functional forms. Orange boxes depict stages of the life cycle that are major targets for drug 
therapy. Nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) target the RT enzyme. Protease inhibitors (HIV-PIs) target 
the protease enzyme. Fusion and entry inhibitors and integrase inhibitors are newer targets for 
drug therapy. Image adapted from
7
. 
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2.2 HIV genetic diversity 
 
There are the two types of HIV that have been identified; namely, HIV-1 and HIV-2
8; 9
. The 
predominant type (HIV-1) is separated into groups M, N, O and P
9; 10
. Group M (comprising 
95% of the complete genome sequences of HIV-1) is further separated into nine subtypes 
being A, B, C, D, F, G, H, J and K
8
 and a growing number of circulating recombinant forms 
(CRFs)
9
 as seen in Figure 2. Subtype C which is the most common subtype world-wide 
accounts for roughly 50% of HIV-1 infections and occurs mainly in sub-Saharan Africa, 
India, Brazil and China, which are the regions of the world that are most heavily affected by 
HIV and AIDS
8; 11
.  
 
A vast number of studies have been done on the interaction of protease inhibitors (PIs) with 
PRs of subtype B HIV origin
12-15
, which occurs mainly in regions of North America and 
Europe. However, fewer studies have been done on the inhibition of non-B subtypes, in 
particular, the subtype C PR
16
. Variation in PI sensitivity between HIV-1 subtypes may be 
significant and contribute to the high prevalence of HIV in sub-Saharan Africa. Genetic 
variation between subtypes usually ranges between 25-35% at the nucleotide level and 
variation within subtypes can range from 15-20%
9; 17
. Thus, both the high mutation rate of 
HIV and the genetic diversity of HIV make it seemingly improbable to create a single PI that 
will maintain potency against all the subtypes of HIV proteases found within different 
individuals
18
.  
15
 Figure 2: Global HIV-1 subtype distribution. Nine subtypes of the major group are 
displayed. As of 16 June 2014, there have been reports of 61 CRFs in HIV-1 group M (Los 
Alamos HIV sequence database, http://www.hiv.lanl.gov/content/sequences/HIV/CRFs/ 
CRFs.html). URFs refer to unique recombinant forms. Image adapted from
11
. 
. 
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2.3 HIV protease and mutations 
 
HIV PR is a 22 kDa homodimer, with each monomer containing 99 amino acid residues
19; 20
. 
Figure 3A, is an illustration of the HIV PR. It belongs to the class of aspartic proteases which 
contain the signature active site amino acid triplet (aspartic acid-threonine-glycine)
21
. Amino 
acid residues comprising the active site of the PR are conserved because mutations in this 
region will be detrimental to its ability to cleave natural substrates
21
. However, mutations 
near/at the active site (primary resistance mutations) and distal (secondary resistance 
mutations) from the active site can impact negatively on the PIs ability to bind the PR
22; 23
. 
Secondary resistance mutations either contribute to drug resistance in the presence of selected 
primary resistance mutations or they may compensate for the reduction in catalytic efficiency 
caused by the selected primary PR resistance mutations
24; 25
. A combination of secondary 
resistance mutations are required to affect the susceptibility of the PR to PIs
12
.  
 
2.4 Protease inhibitors 
 
PIs are designed to target the active site of the PR; thereby, inhibiting its ability to bind and 
cleave natural substrates. The first-line antiretroviral therapy (ART) guidelines for adults and 
adolescents include the use of two nucleoside reverse transcriptase inhibitors in combination 
with one non-nucleoside reverse transcriptase inhibitor
26
. Second-line ART may proceed 
upon failure of the first-line ART regimen in an individual. Currently, there are 10 FDA 
approved PIs; namely, saquinavir, indinavir, amprenavir, ritonavir, nelfinavir, lopinavir, 
atazanavir, fosamprenavir, tipranavir and darunavir. Protease inhibitors (PIs) preferred in 
second-line ART for adults and adolescents are either atazanavir, darunavir or lopinavir in 
combination with the PI booster, ritonavir
26
.  
17
 Figure 3: Polymorphic sites in subtype B and C-SA PRs. (A) The flexible flaps of PR 
(residues at positions 46–54) are coloured cyan. The fulcrum coloured purple (residues at 
positions 10–23), hinge coloured pink (residues at positions 35–42 and 57–61) and cantilever 
coloured blue (residues at positions 62–78) are regions implicated in flap opening.  Locations 
of the eight polymorphic amino acids in each monomer are shown as spheres. PDB ID: 
3U71
27
. Spheres indicate the position of polymorphisms in the structure in comparison to the 
consensus subtype B PR and numbers correspond to the amino acid position in the primary 
sequence. (B) Representation of darunavir (grey sticks surrounded by spheres) bound to the 
HIV-1 subtype B PR. PDB ID: 4LL3
28
.  The spheres, showing the area filled by darunavir 
upon binding, encompass the active site region of the PR. The catalytic aspartic acid (position 
25) of each monomer of the PR is represented by sticks. Figures generated using PyMOL 
(Schrödinger LLC., Portland, USA; http://www.schrodinger.com).  
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All of the clinically used PIs are competitive active site inhibitors and, except for tipranavir, 
all are peptidomimetics
29
. Peptidomimetics are non-cleavable chemical structures designed to 
convey characteristic information contained in peptides into small non-peptide structures, 
thereby mimicking peptides
30
. Figure 3B is an illustration of the HIV-1 subtype B PR bound 
to the peptidomimetic PI, darunavir
28
. 
 
The first generation PI, ritonavir, is no longer used as an inhibitor alone, rather as a boosting 
agent in highly active antiretroviral therapy (HAART) with other PIs, due to its ability to 
inhibit the CYP-450 3A4 isoform
31
. Atazanavir is a second generation PI which is the 
bulkiest of the currently available FDA-approved PIs
29
. The second generation inhibitor, 
darunavir, is the latest FDA-approved PI and has been described as the most potent PI 
currently available. Darunavir is also described as being highly active against multi-drug 
resistant PRs which is attributed to its ability to fit within the “substrate envelope”32; 33 of the 
active site during binding
34
. Darunavir differs only by the addition of a bis-tetrahydrofuranyl 
(bis-THF) moiety to the structure of amprenavir, which form vital hydrogen bonding 
interactions with the main chain of Asp29 and Asp30 in the PR
29; 34
, allowing darunavir to 
mimic conserved hydrogen bonds made by Gag and Gag-Pol substrates
35
.  
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2.5 Catalytic mechanism of HIV protease 
 
The mature HIV PR is released from the Gag-Pol polyprotein precursor via a two-step 
mechanism
36-40
. The first step appears to occur via intramolecular cleavage of the p6
Pol–PR 
junction (Chapter 1, Figure 2)
39
. This is the faster step of PR maturation. The flanking C-
terminal sequence does not appear to hinder catalytic activity. The activity of PR attached to 
flanking RT residues is comparable to mature PR
39; 40
.  The slower cleavage of the PR-RT 
junction is achieved by an intermolecular catalytic mechanism
39; 40
. Therefore, processing of 
other cleavage sites in Gag, Gag-Pol and Nef may be performed by either PR attached to 
flanking RT residues or mature PR. Previous 
18
O-exchange mass spectrometry studies 
involving HIV PR and its substrate analogues show that peptide hydrolysis proceeds through 
the formation of a reversible and metastable gem-diol intermediate
41
. Near-atomic resolution 
crystal structures of HIV PR have captured important components of the reaction 
mechanism
42
. A substrate is initially recognised and binds to the PR enzyme (ES). Thereafter, 
it is converted to a gem-diol intermediate (ES
*
) through nucleophilic attack by an activated 
water molecule (Figure 4). Covalent linkages in the substrate are broken resulting in the 
formation of two products (P1 and P2). The products are then released sequentially and the PR 
may hydrolyse another substrate. The two catalytic residues (D25 and D25ʹ) perform a vital 
general acid-base role to activate the nearby water molecule which acts as a nucleophile and 
attacks the carbonyl carbon of the scissile bound. Previous studies on the pH dependence of 
the hydrolysis reaction catalysed by HIV PR reveal that substrates and inhibitors only bind to 
the PR when one of the two catalytic aspartic acid side-chains are protonated
43-45
. The pKa 
values of the catalytic aspartic acid side-chains are highly dependent on their surrounding 
environment. These side-chains have different pKa values of 3.1 and 5.2
43
 and in the presence 
of a pepstatin inhibitor, one aspartic acid is protonated in the pH range of 2.5–6.544.    
20
 Figure 4: HIV protease reaction mechanism. Generalised reaction mechanism for all HIV 
PR substrates is displayed. A water molecule is located at the catalytic dyad (D25 and D25ʹ) 
in the unbound PR and is activated by the unprotonated aspartate group.  Image adapted 
from
42
. 
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2.6 South African HIV-1 subtype C protease (C-SA PR) 
 
Currently, over 100 000 macromolecular structures have been deposited in the Protein Data 
Bank (PDB). Roughly 600 of these are of HIV PRs. Thus far, the majority of PR crystal 
structures in the PDB are representative of HIV-1 subtype B and only three crystal structures 
of HIV-1 subtype C PRs had been solved prior to the current study
46; 47
. The previous 
structures of subtype C PRs represent those with a sequence matching a patient from India 
(comprising the N37A and K41R polymorphisms in comparison to the C-SA PR), including 
the 1.2 Å high-resolution structure of the unbound subtype C PR which provided important 
basic information about the subtype C PR and a basis for expansion in the current study
47
.  
Interestingly, genetic diversity occurs within subtypes of HIV owing to the ever-mutating 
nature of the virus as well as mutations resulting from selective pressure from antiviral 
drugs
9; 17
. The consensus sequence of the HIV subtype C PR occurring in South Africa (C-SA 
PR) shares the same sequence identity as the consensus subtype C PR in group M (Los 
Alamos HIV sequence database, http://www.hiv.lanl.gov/). The C-SA PR differs at eight 
amino acid residues in each monomer (Figure 3A) to the consensus subtype B PR (Los 
Alamos HIV sequence database, http://www.hiv.lanl.gov/). The consensus C-SA PR (wild-
type) sequence data were obtained from Prof Lynn Morris (AIDS Virus Research Unit, 
National Institute of Communicable Diseases, South Africa). The M36I, L89M and I93L 
polymorphisms inherent to the C-SA PR are associated with drug resistance to multiple PIs in 
subtype B HIV-1. Therefore, these polymorphisms are referred to as secondary resistance 
mutations. Amprenavir, indinavir, nelfinavir and saquinavir displayed 3–6 fold weaker 
binding, whereas, lopinavir and ritonavir displayed 8–24 fold weaker binding to the C-SA PR 
in comparison to the subtype B PR
16
. Importantly, naturally occurring polymorphisms in 
22
strains such as subtype C HIV-1 have an additive effect to primary resistance mutations and 
amplification of drug resistance mutations
48; 49
. 
 
2.7 Protease dynamics and flap conformers 
 
Crystal structures of HIV-1 PRs when combined with activity data provide a good idea of 
structure-function relations. However, proteins are naturally highly dynamic and crystal 
structures only provide a static representation of proteins. The vast majority of studies 
measuring PR dynamics are investigated using molecular dynamics (MD) simulations. MD 
simulation results require careful attention for correct interpretation and are useful when 
complemented with experimental data. Other analyses of PR dynamics have been 
investigated using nuclear magnetic resonance (NMR)
50-52
, which is limited by the modest 
sensitivity of the technique, and spin-labelled pulsed electron paramagnetic resonance (EPR) 
spectroscopy
53; 54
, which was used to exclusively measure distances between flap residues. 
 
HIV PR may exhibit a number of flap conformations in solution. The majority of PR 
molecules prefer a semi-open conformation in solution (Figure 5B)
54
. At baseline, an 
ensemble of semi-open conformers may exist. The semi-open conformers may directly 
interchange with a closed conformer (Figure 5A). Structural and dynamics studies of HIV-1 
PR indicate that a curled flap conformation (top view of Figure 5C) is an intermediate state 
which allows for the formation of the fully-open conformer (Figure 5C)
50; 55; 56
. No x-ray 
diffracted structural data is available for both the curled and fully-open conformer. The curled 
conformer is described by a pronounced curling of the flap tips
56
. The fully-open conformer 
also displays inward curling of the flap tips (residue positions 48–52) accompanied by 
upward and outward motion of the flap-hinge region from the active site
57
. Entry of a 
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substrate or inhibitor to the active site of the PR requires substantial movement of the flaps (~ 
15 Å from their position in the closed conformer)
58
. Therefore, it is accepted that only the 
fully-open conformation allows for substrate/inhibitor binding.  
 
Complete flap opening occurs through concerted downward movement of the hinge (residue 
positions 35–42 and 57–61 of each monomer), cantilever (residue positions 62–78) and 
fulcrum (residue positions 10–23) regions (Figure 3)) which results in the upward and 
outward motion of the flaps (Figure 5C)
57
. Distance measurements using spin-labelled pulsed 
EPR spectroscopy, displayed an increased proportion of the curled and fully-open conformers 
(Figure 5C) in the subtype C PR population relative to other HIV-1 PRs
54
. The majority of C-
SA PR molecules display semi-open flaps; though, there is a definite shift in the equilibrium 
between semi-open, curled and fully-open conformers. Combined EPR spectroscopy and 
NMR experiments have identified and verified the population of flap conformers in the apo-
state and during inhibitor binding for the subtype B and C HIV-1 PRs
59
. These experiments 
did not fully elucidate the mechanism for the reduced drug susceptibility displayed by the 
subtype C HIV-1 PR; however, differences in the population of flap conformers may be vital 
for the interpretation of other dynamic comparisons of the subtype B and C-SA PRs. 
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 Figure 5: Overview of flap conformers displayed by HIV-1 PR. The closed (A), semi-
open (B) fully-open (C) conformers are in dynamic equilibrium. Above the respective three-
dimensional structures are the top views of the flaps. The semi-open flap conformation is the 
most prevalent conformer in the absence of inhibitor. The presence of protease inhibitors 
promote the closed form of the PR. Crystal structure data is unavailable for a fully-open 
conformer which is characterised by upward and outward displacement of the flap-hinge 
region. Representation of the flap positioning of the fully-open conformer is based on MD 
simulation models
57
. The fully-open conformer may also be referred to as a wide-open 
conformer; however, fully-open is preferred in the current study due to previous misuse of 
the term “wide-open”60. PDB ID: 1HXW (A)61, 1HHP (B and C)62 and 3UHL (C)63.  
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 Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) experiments may provide a 
straight forward comparison of protein dynamics between the C-SA PR and subtype B PR. 
Measuring amide hydrogen/deuterium exchange (HDX) via mass spectrometry over several 
time points allows for the determination of HDX rates in detected peptides. HDX-MS has 
been employed to elucidate the solvent protection patterns and protein dynamics of reverse 
transcriptase monomers
64
 and the mature and immature HIV-1 capsid proteins
65-67
. There has 
been no report on the investigation of HIV PR dynamics using HDX-MS. Thus, the current 
study provides novel results and insights into the dynamics at different regions of the HIV-1 
PR and the mechanism of reduced drug susceptibility displayed by the C-SA PR.  
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2.8 Aim and objectives 
 
The HIV-1 subtype C PR may be described as having increased virulence in comparison to 
other HIV-1 subtypes. This implies that HIV-1 subtype C strains may display improved viral 
fitness. The recent increased prevalence of this subtype in the Americas and Europe, where it 
had previously been detected at low levels in these populations, supports this statement
68-72
. 
The aim of the current research was to identify functional differences between the subtype B 
and C-SA PRs and explain any differences through structural and dynamic characterisation. 
The specific objectives of this research were to: 
1. Express and purify the subtype B and C-SA PRs at high yields to allow for energetic, 
structural and dynamic evaluation. 
2. Investigate the steady-state kinetics for substrate processing for both PRs using 
fluorescence-based activity assays. 
3. Determine inhibition constants of atazanavir, darunavir and ritonavir for both PRs by 
performing fluorescence-based inhibition assays.  
4. Evaluate the energetics and mode of binding of the aforementioned inhibitors to both PRs 
using isothermal titration calorimetry. Binding energetics of atazanavir and darunavir for the 
subtype B PR have been determined previously under the conditions used in the current 
research
13; 14
. 
5. Resolve the three-dimensional crystal structure of the apo-C-SA PR using x-ray 
crystallography. The atomic structure of the consensus subtype B PR has been solved 
previously
55
. 
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6. Identify differences in flap dynamics between the subtype B and C-SA PRs by performing 
molecular dynamics simulations.  
7. Investigate the dynamics of HIV-1 PR at all regions and determine differences in protein 
dynamics between the subtype B and C-SA PRs via hydrogen/deuterium exchange-mass 
spectrometry experiments.  
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CHAPTER 3 
 
Structural Insights into the South African HIV-1 Subtype C 
Protease: Impact of hinge region dynamics and flap flexibility 
in drug resistance 
 
Previn Naicker, Ikechukwu Achilonu, Sylvia Fanucchi, Manuel Fernandes, Mahmoud A.A. 
Ibrahim, Heini W. Dirr, Mahmoud E.S. Soliman and Yasien Sayed.  
 
J. Biomol. Struct. Dyn. 31, 1370-1380. (2013). 
 
 
In this publication, the crystal structure of the apo-C-SA PR was determined and compared to 
that of the apo-subtype B PR. Altered dynamics at the flap tips of the C-SA PR was 
identified. 
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The HIV protease plays a major role in the life cycle of the virus and has long been a target in antiviral therapy.
Resistance of HIV protease to protease inhibitors (PIs) is problematic for the effective treatment of HIV infection. The
South African HIV-1 subtype C protease (C-SA PR), which contains eight polymorphisms relative to the consensus
HIV-1 subtype B protease, was expressed in Escherichia coli, purified, and crystallized. The crystal structure of the
C-SA PR was resolved at 2.7Å, which is the first crystal structure of a HIV-1 subtype C protease that predominates in
Africa. Structural analyses of the C-SA PR in comparison to HIV-1 subtype B proteases indicated that polymorphisms at
position 36 of the homodimeric HIV-1 protease may impact on the stability of the hinge region of the protease, and
hence the dynamics of the flap region. Molecular dynamics simulations showed that the flap region of the C-SA PR
displays a wider range of movements over time as compared to the subtype B proteases. Reduced stability in the hinge
region resulting from the absent E35-R57 salt bridge in the C-SA PR, most likely contributes to the increased flexibility
of the flaps which may be associated with reduced susceptibility to PIs.
An animated interactive 3D complement (I3DC) is available in Proteopedia at http://proteopedia.org/w/Journal:JBSD:36
Keywords: HIV-1 protease; South African subtype C; hinge region; salt bridge; flap region; flexibility; crystal structure;
molecular dynamics
Introduction
Human immunodeficiency virus (HIV) continues to be
one of the most problematic pathogens known to man.
HIV infection progresses to acquired immunodeficiency
syndrome (AIDS) resulting in extreme suppression of the
immune system in infected individuals. The production of
effective drugs against HIV has been an uphill battle
which is attributed to its reverse transcriptase (RT), which
is prone to introducing mutations into the viral genome
(Bebenek, Abbotts, Roberts, Wilson, & Kunkel, 1989).
Due to the mutation-prone nature of RT and the high rep-
lication rate of HIV, alterations and mutations occur often
in viral proteins for which antiviral drugs have been
designed to target; thereby, providing a challenge for the
production of effective antivirals (Bebenek et al., 1989).
One such protein is the HIV protease (PR), which cleaves
immature viral polyproteins into mature and functional
proteins, for the production of infective virions (Tomass-
elli & Heinrikson, 2000). HIV PR targets 12 cleavage
sites in Gag and Gag-Pol polyproteins (De Oliveira et al.,
2003). Thus, the PR has been identified as a major target
in HIV therapy (Tomasselli & Heinrikson, 2000).
Two types of HIV have been identified: HIV-1 and
HIV-2 (McCutchan, 2006; Taylor, Sobieszczyk,
McCutchan, & Hammer, 2008). The predominant type
(HIV-1) is separated into groups M, N, O, and P (Plan-
tier et al., 2009; Taylor et al., 2008). Group M (Major
group) is further separated into nine subtypes (A, B, C,
D, F, G, H, J, and K) and a growing number of circulat-
ing recombinant forms (McCutchan, 2006). HIV-1
subtype C is the most common subtype worldwide,
occurring mainly in sub-Saharan Africa, India, Brazil,
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and China (McCutchan, 2006), and is responsible for
50% of global HIV-1 group M infections (Buonaguro,
Tornesello, & Buonaguro, 2007). Genetic variation
between subtypes usually ranges between 25 and 35% at
the nucleotide level and variation within subtypes can
range from 15 to 20% (Hemelaar, Gouws, Ghys, &
Osmanov, 2006; McCutchan, 2006). Thus, both the high
mutation rate within the HIV PR and the genetic diver-
sity of HIV increase the challenge of producing a prote-
ase inhibitor (PI) that is capable of inhibiting the PRs of
various HIV subtypes found within different individuals
(Kantor & Katzenstein, 2003).
The homodimeric HIV-1 PR, consisting of 99 amino
acids per monomer (Figure 1(A)), belongs to a class of
aspartyl PRs which contain the signature active site
amino acid triplet (aspartic acid-threonine-glycine)
(Wlodawer & Vondrasek, 1998). The hinge region of the
PR is closely associated with the stability and movement
of the flap region (position 46–54); Figure 1(B). We
define the hinge region as comprising residues from
positions 35–42 and 57–61. The PR flaps undergo sub-
stantial movement allowing for substrate/inhibitor entry
(open conformation) and form key interactions during
the binding of substrate/inhibitor (closed conformation)
(Gustchina & Weber, 1990). Therefore, the flaps are
required to display flexibility; however, increased flexi-
bility may result in reduced substrate processing and PI
resistance (Meiselbach, Horn, Harrer, & Sticht, 2007).
Increased flexibility of the flap-hinge region is likely to
result in increased flexibility of the flaps, as seen in PRs
that are resistant to the PI, amprenavir (Meiselbach
et al., 2007).
The HIV-1 subtype C PR that predominates in South
Africa (C-SA PR) is defined as the consensus subtype C
PR (Los Alamos HIV sequence database, http://www.hiv.
lanl.gov/). In this study, the C-SA PR was recombinantly
expressed in E. coli, purified from inclusion bodies, crys-
tallized, and its detailed three-dimensional structure
solved. Structural analyses of the C-SA PR, as well as
the consensus subtype B PR (Los Alamos HIV sequence
database, http://www.hiv.lanl.gov/), and a multidrug
resistant subtype B PR (subtype B-MDR PR) were per-
formed. Molecular dynamics (MD) simulations were per-
formed to determine the differences in flap movement
and residue-specific fluctuation amongst the PRs. This
study highlights the variability found in the flap-hinge
region amongst subtype B PRs and the C-SA PR, as
well as its impact on flap movement and resistance to
clinically available PIs.
Materials and methods
Expression and purification
The C-SA PR sequence data were obtained from Prof
Lynn Morris (AIDS Virus Research Unit, NICD of
Johannesburg, South Africa). The recombinant pET-11b
plasmid encoding a subtype B PR gene was a kind gift
from Dr. J. Tang (University of Oklahoma Health Sci-
ences Center, Oklahoma City). The mutations (T12S,
I15V, L19I, M36I, R41K, H69K, L89M, and I93L) con-
stituting the baseline sequence of the C-SA PR were
generated previously in our lab (Mosebi, Morris, Dirr, &
Sayed, 2008), by site-directed mutagenesis using the
QuikChange method (Stratagene, La Jolla, CA, USA). A
Q7K point mutation was introduced to reduce PR auto-
catalysis (Mildner et al., 1994). DNA sequencing con-
firmed the coding region of the C-SA PR.
Escherichia coli BL21 (DE3) pLysS cells trans-
formed with the plasmid encoding the C-SA PR gene
were induced to express the C-SA PR as inclusion
bodies by the addition of isopropyl-β-D-thiogalactopyra-
noside (Ido, Han, Kezdy, & Tang, 1991). Cells were dis-
rupted by sonication and centrifuged after overexpression
of the PR. PR was recovered from the inclusion bodies
using 8M urea, 10mM Tris-HCl, and 2mM dithiothrei-
tol (DTT) (pH 8.0) buffer. The positively charged PR
was allowed to flow through a diethylaminoethyl ion-
exchange matrix at pH 8.0. The PR was dialyzed against
formic acid and was refolded by dialysis against 10mM
sodium acetate, 2mM NaCl, 1mM DTT, and 5% glyc-
erol (pH 5.0) buffer. The PR was further purified using
CM-Sepharose ion-exchange column chromatography,
with a 0–1M NaCl gradient elution. The PR was finally
dialyzed against 10mM sodium acetate, 2mM NaCl, and
Figure 1. (A) Structure of unbound HIV-1 PR with the active
site triplet shown as sticks, hinge region in magenta, and flaps
in blue (PDB ID: 2PC0). (B) Multiple sequence alignment of
the C-SA PR, consensus subtype B PR, subtype B-MDR PR,
and subtype C-2R8N PR. Active site triad shown in bold,
hinge region in magenta, and flaps in blue. Both the C-SA PR
and the consensus subtype B PR under investigation exhibit the
Q7K mutation which reduces protease autocatalysis (Mildner
et al., 1994).
Structural insights into the South African HIV-1 subtype C protease 1371
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1mM DTT (pH 5.0) buffer. Purity of the PR was evalu-
ated by tricine-SDS-PAGE (Laemmli, 1970; Schägger,
2006). The concentration of the PR was determined
using a molar extinction coefficient of 25,480M1 cm1
from absorbance spectra obtained on a Jasco V-630 spec-
trophotometer.
Enzyme activity determination
The specific activity of the C-SA PR was determined fol-
lowing hydrolysis of the HIV-1 PR fluorogenic substrate
(Abz-Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2) which
mimics the capsid/P2 cleavage site in the HIV-1 Gag
polyprotein. An increase in fluorescence emission from
the 2-aminobenzoyl group was detected at an excitation
wavelength of 337 nm and emission wavelength of
425 nm, resulting from cleavage of the Nle-Phe(NO2)
peptide bond (Carmel & Yaron, 1978; Szeltner & Polgar,
1996). A substrate concentration of 50 μM and an
enzyme concentration of 10–50 nM, with an excitation
bandwidth of 2.5 nm and emission bandwidth of 5 nm
were used for the 1min measurements during steady
state. The intensity signal associated with complete
cleavage of 1 nmol of substrate was measured and used
to convert intensity to activity.
Active site titration
The percentage of active enzyme in the protein prepara-
tion was determined using isothermal titration calorime-
try (ITC). Briefly, 192.5 μM of acetyl-pepstatin (an
aspartyl PR inhibitor) was titrated against 12.75 μM of
C-SA PR in 10 μl injections at 293.8K using a VP-ITC
microcalorimeter. The heat due to dilution of acetyl-
pepstatin was subtracted from the data-set and any
baseline errors were corrected. The changes in heats
were integrated and fitted using one set of binding sites
(Origin 5.0 software package). The percentage of active
sites was determined from the calculated stoichiometry
value; a value of 1 indicates a 100% active enzyme
preparation.
Crystallization and data collection
C-SA PR crystals were grown at 293K using the hang-
ing-drop vapor diffusion method in a 24-well microplate.
Conditions allowing for optimal crystal growth were
screened using the Hampton Research Index HR2-144
(Hampton Research). Using a reservoir buffer comprising
0.2M sodium citrate tribasic dihydrate in 20% polyethe-
lene glycol 3 350 resulted in the formation of diffraction
quality PR crystals. The stock protein concentration used
for crystallization was 0.5mg/ml in 10mM sodium ace-
tate, 2mM NaCl, and 1mM DTT (pH 5.0). Each hang-
ing drop (4 μl or 8 μl) comprised equal volumes of
reservoir buffer and stock protein. A paraffin–silicone oil
mixture (1:1 ratio) covered the reservoir buffer in each
well (Chayen & Stewart, 1992). Single crystals were
mounted on a cryoloop, briefly soaked in reservoir solu-
tion containing a higher concentration of cryoprotectant
(polyethelene glycol), and frozen in liquid nitrogen. X-
ray diffraction data were collected in-house on a Bruker
X8 Proteum system with a Microstar copper rotating-
anode generator with Montel 200 optics, a PLATINUM
135 CCD detector, and an Oxford Cryostream Plus sys-
tem. During data collection, the crystal was maintained
at 113K in a stream of nitrogen gas. Images were col-
lected covering an oscillation angle of 0.5° per image.
The data-set was processed using APEX and SAINT
software (Bruker AXS Inc., Madison, WI, USA).
Model building and structure refinement
The phases of the structure were solved by the molecular
replacement method using MOLREP (Vagin & Teplyakov,
2000); a component of the CCP4i suite of programs
(Potterton, Briggs, Turkenburg, & Dodson, 2003). A sub-
type C isoform with the following variations as compared
to the C-SA PR: L33I, N37A, K41R, and L63I was used
as a search probe for molecular replacement (PDB ID:
2R8N; Coman, Robbins, Goodenow, McKenna, & Dunn,
2007). Model building was performed using Coot (Emsley
& Cowtan, 2004); thereafter, cycles of global reciprocal
space refinement using REFMAC5 (Murshudov, Vagin, &
Dodson, 1997) and local real space refinement using Coot
(Emsley & Cowtan, 2004) were performed. Stereochemi-
cal validation of the target model was performed using
MolProbity (Chen et al., 2010) and PROCHECK (Las-
kowski, 1993). The PyMOL Molecular Graphics System
(Schrödinger LLC., Portland, USA; http://www.schroding-
er.com) was used to generate images of the structure.
Sequence alignment was performed using Clustal X 2.0
(Higgins & Sharp, 1988; Larkin et al., 2007).
MD simulations
The simulations of the three enzyme systems: C-SA PR
(PDB ID: 3U71), consensus subtype B PR (PDB ID:
2PC0), and subtype B-MDR PR (PDB ID: 1RPI) were
performed under physiological pH conditions. The aspar-
tic acid residue (D25) of the catalytic site exhibits an
increased pKa value of 5.2 in the inhibitor bound PR
(Shen, Wang, Kovalevsky, Harrison, & Weber, 2010)
while no increased pKa was reported for the free form of
the PR (pKa = 4.5) (Smith, Brereton, Chai, & Kent,
1996). Therefore, an unprotonated active site was used
throughout the MD studies, as this is the prevalent form
at physiological pH. Hydrogen atoms of the proteins
were added using the Leap module in Amber10 (Case
et al., 2005). The standard AMBER force field for bioor-
ganic systems (ff03) (Duan et al., 2003) was used to
define the HIV-1 PR enzyme parameters. Counter ions
were added to neutralize the enzyme. The system was
enveloped in a box of equilibrated TIP3P (Jorgensen,
1372 P. Naicker et al.
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Chandrasekhar, Madura, Impey, & Klein, 1983) water
molecules with 8Å distance around the enzyme.
The MD package Amber10 (Case et al., 2005) was
used for the minimization and equilibration protocols.
Cubic periodic boundary conditions were imposed and
the long-range electrostatic interactions were treated with
the particle-mesh Ewald method (Essmann et al., 1995)
implemented in Amber10 with a nonbonding cut-off dis-
tance of 10Å. The energy minimization was performed
using the steepest descent method in Amber10 for 1000
iterations and switched to conjugate gradient for 2000
steps, with a restraint potential of 500 kcal/mol Å2
applied to the solute. The entire system was then freely
minimized for 1000 iterations. For the equilibration and
subsequent production run, the SHAKE algorithm
(Ryckaert, Ciccotti, & Berendsen, 1977) was employed
to constrain all bonds involving hydrogen atoms, allow-
ing for an integration time step of 2 fs. Harmonic
restraints with force constants 2 kcal/mol Å2 were applied
to all solute atoms. A canonical ensemble (NVT) MD
was carried out for 50 ps, during which the system was
gradually annealed from 0 to 300K using a Langevin
thermostat with a coupling coefficient of 1/ps. Harmonic
restraints with force constraints 10 kcal/mol Å2 were
applied to all solute atoms during the heating stage. Sub-
sequently, the system was equilibrated at 300K with a
2 fs time step for 500 ps while maintaining the force con-
stants on the restrained solute. With no restraints
imposed, a production run was performed for 10 ns in an
isothermal isobaric (NPT) ensemble using a Berendsen
barostat (Berendsen, Postma, van Gunsteren, DiNola, &
Haak, 1984) with a target pressure of 1 bar and a pres-
sure coupling constant of 2 ps. The coordinate file was
saved every 1 ps and the trajectory was analyzed every
10 ps using the Ptraj module implemented in Amber10.
Results and discussion
C-SA PR preparation
The recombinant expression of the C-SA PR yielded
0.2mg/l of culture. The purity of the C-SA PR was esti-
mated to be > 99%, which is required for the ITC and
crystallography studies. The C-SA PR was shown to be
enzymatically active following hydrolysis of the HIV-1
PR fluorogenic substrate (Abz-Arg-Val-Nle-Phe(NO2)-
Glu-Ala-Nle-NH2) (Figure 2). The specific activity of the
C-SA PR derived from the slope of the plot in Figure 2
is 79 μmolesmin1mg1. Figure 3 shows a binding ther-
mogram of the C-SA PR titrated with the aspartyl PR
inhibitor, acetyl-pepstatin. Acetyl-pepstatin binds weakly
to the C-SA PR showing a calculated Kd of 192 nM
which is employed in displacement titration reactions for
high affinity inhibitors (Velázquez-Campoy, Kiso, & Fre-
ire, 2001). This titration allows for the calculation of the
percentage of active PR in solution (active site concen-
tration), which was calculated to be 82%, derived from a
stoichiometry value of 0.82. These findings indicate that
the solved C-SA PR is enzymatically active.
Crystal structure of the C-SA PR
The current study is the first to report on the detailed
structure of the C-SA PR. The only other subtype C PR
structures to be solved to date are of a PR which pre-
dominates in India (subtype C-2R8N PR) (Coman et al.,
2007, 2008). The C-SA PR being the consensus HIV-1
subtype C PR and subtype C being the most common
subtype worldwide (McCutchan, 2006), emphasize the
importance of this study. Structural homology analysis of
the C-SA PR and the subtype C-2R8N PR revealed no
significant RMSD in respect to the hinge and flap
regions. The coordinates for the 2.7 Å resolution C-SA
PR structure were deposited in the Protein Data Bank
(PDB ID: 3U71). Stereochemical validation of the C-SA
PR structure revealed no disallowed bond angles or rota-
mers for all of the constituent residues (Table 1). All
water molecules were removed from the structure prior
to being deposited in the PDB. The removal of water
molecules was implemented because all solvent mole-
cules could not be resolved accurately at 2.7Å. How-
ever, this had no impact on the overall structure of the
PR. The space group and unit cell parameters match pre-
viously described unbound HIV-1 PR crystals (Heaslet
et al., 2007; Yedidi et al., 2011). A Matthews coefficient
(VM) of 2.45Å
3Da1 and a solvent content of 49.75%
indicate a PR monomer as the asymmetric unit of each
unit cell of the C-SA PR crystal, which is a common
finding for crystals of unbound HIV PR (Heaslet et al.,
2007; Yedidi et al., 2011).
Figure 2. Specific activity of the C-SA PR. Determined
following hydrolysis of the HIV-1 protease substrate (Abz-Arg-
Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2) in 50mM sodium acetate
and 1M NaCl (pH 5.0) at 293K.
Structural insights into the South African HIV-1 subtype C protease 1373
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Structural analyses of the C-SA PR
Figure 1(B) shows a sequence alignment of the C-SA
PR with the consensus subtype B PR (Heaslet et al.,
2007), subtype B-MDR PR (Logsdon et al., 2004), and
subtype C-2R8N PR (Coman et al., 2008). The subtype
C-2R8N PR contains the following mutations relative to
the C-SA PR: L33I, N37A, K41R, and L63I. The C-SA
PR displays high structural homology with the subtype
C-2R8N PR; however, notable differences occur at posi-
tions 37 and 41 which are located in the hinge region of
the PR. In subtype B PRs, M36 was shown to form con-
tacts with residues in the 10s loop (Clemente et al.,
2004; Martin et al., 2005). These contacts are absent in
the subtype C-2R8N due to the M36I and I15V
polymorphisms (Coman et al., 2008). These contacts as
expected are also absent in the C-SA PR, and probed
further investigation of the contacts occurring in the
hinge region of the C-SA PR which are closely related
to flap dynamics (Coman et al., 2008). The subtype
B-MDR PR exhibits the following 11 mutations relative
to the consensus subtype B PR: L10I, D25N, M36V,
M46L, I54V, I62V, L63P, A71V, V82A, I84V, and
L90M. The subtype B-MDR PR displays high-level drug
resistance and cross-resistance to PIs (Palmer, Shafer, &
Merigan, 1999; Logsdon et al., 2004). The V82A and
I84V active site mutations allow for expansion of the
active site which is a mechanism implicated in drug
resistance (Logsdon et al., 2004). The implication of the
M36V mutation in drug resistance is an important
consideration, as the M36I mutation in HIV-1 PRs is
thought to be a secondary drug resistance mutation
(Patick et al., 1998). The C-SA PR exhibits the follow-
ing eight mutations relative to the consensus subtype B:
T12S, I15V, L19I, M36I, R41K, H69K, L89M, and
I93L, which occur distal to the active site. The M36I
mutation being considered to be a secondary drug
resistance mutation (Patick et al., 1998), which occurs in
Figure 3. Active site titration of the C-SA PR with acetyl-
pepstatin. The raw calorimetric data is indicated in the upper
panel and the integrated heats for the above peaks plotted
against the molar ratio of acetyl-pepstatin to protease dimer in
the lower panel. The peak contributing to the heat signal below
baseline was corrected for in the fitting procedure. Acetyl-
pepstatin was titrated until binding sites on the PR were
saturated in a buffer comprising 10mM sodium acetate (pH
5.0) at 293K.
Table 1. Data collection and refinement statistics for the
C-SA PR structure.
Wavelength (Å) 1.5418
Space group P 41 21 2
Unit-cell parameters
a, b, c (Å) 45.928, 45.928, 99.960
α, β, γ (°) 90.00, 90.00, 90.00
Resolution range (Å) 2.72–41.73 (2.72–2.79)
No. of observed reflections 43,511
No. of unique reflections 3193
Completeness (%) 98.8
I/σ(I) 5.18 (3.00)
Rmerge
a 0.200 (0.413)
Final overall R factor 0.220
Rwork
b 0.217
Rfree
b 0.283
No. of protein atoms 755
No. of ligand atoms 0
Average B value (Å2) 25.79
RMSD in bond length (Å) 0.017
RMSD in bond angles (°) 1.776
Ramachandran statistics
Outliers (%) 0
Favored (%) 96.91
VM (Å
3Da1) 2.45
Solvent content (%) 49.75
Asymmetric unit content monomer
PDB ID 3U71
aRmerge =
P
hkl
P
i |Ii(hkl) – (I(hkl))| /
P
hkl
P
i |Ii(hkl)|, where I(hkl)
is the intensity of reflection hkl,
P
hkl is the sum over all reflections
and is the sum over i measurements of reflection hkl.
bRfree is calculated for a randomly chosen 5% of reflections which
were not used for refinement of the structure and Rwork is calcu-
lated for the remaining reflections. Data in brackets refer to the
highest resolution shell.
1374 P. Naicker et al.
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the hinge region of the PR, probed further investigation
into the interactions occurring in this region. The overall
tertiary folds of the PRs under investigation do not differ
significantly (Figure 4). The subtype B-MDR PR
(magenta) is shown to crystallize with its flaps in a wider
open conformation. More detailed analyses of the struc-
tures are required in order to determine the effects of
polymorphisms between the subtypes on the dynamics of
these enzymes.
E35 in HIV PR maintains long-range interactions
within the PR polypeptide chain (Swairjo, Towler,
Debouck, & Abdel-Meguid, 1998). The absence of the
E35-R57 salt bridge (ion pair) in both monomers of the
C-SA PR is indicated in Figure 5(A). R57 in the C-SA
PR adopts a different rotamer to that of the R57 in the
subtype B PRs, resulting in an inability to form a salt
bridge with E35. The backbone of R57 only forms back-
bone hydrogen bonds with V77 that form part of a
β-sheet located in a region interior to the flaps which are
maintained in all the structures under investigation. I36
(green) displays no contacts with other residues in the
hinge region. The absence of the E35-R57 (side chain-
side chain) salt bridge in PRs results in an apparent
outward movement of the flaps (Swairjo et al., 1998).
Figure 5(B) shows that the consensus subtype B PR
exhibits the E35-R57 salt bridge in one of its monomers,
as well as a hydrogen bond between the side chain of
R57 and backbone of M36 (cyan). The other monomer
shows the side chain of R57 also interacts with the back-
bone of M36 which may assist in maintaining the
compact conformation of the hinge region, as seen by
the close proximity of E35 and R57. Figure 5(C) shows
the subtype B-MDR PR exhibits the E35-R57 salt bridge
in both monomers. The backbone of V36 (magenta)
exhibits hydrogen bonds with the side chain of E35 and
not R57.
The E35-R57 salt bridge is the only possible ion pair
present in the hinge region of HIV-1 PR. Thermody-
namic studies using ITC revealed that the CRF01_AE
strain of PR containing D35 and I36, which also lacks a
salt bridge between the residues at position 35 and 57,
displays reduced binding affinity to inhibitors nelfinavir
and darunavir when compared to the E35 and M36 sub-
type B PR (Bandaranayake et al., 2010). Calculated
binding free energies reveal reduced binding affinity to
amprenavir for a E35D HIV-1 PR mutant (Meiselbach
et al., 2007). The mutant showed a stable salt bridge
over short periods (0–1 and 8.3–9.3 ns), whereas a stable
salt bridge is established over the entire 10 ns simulation
in the E35 HIV-1 PR (Meiselbach et al., 2007). These
findings suggest that an absence of the E35-R57 salt
bridge highlighted in this study may be implicated in
drug resistance mechanisms.
The displacement of the flap tips, residues 49–52
forming a hairpin loop, in the absence of a hinge region
salt bridge occurs in the plane perpendicular to the plane
of the hairpin loop (Swairjo et al., 1998). In some cases,
minor displacement (< 1.2Å) results in the backbone
atoms of the flap tips being out of hydrogen bonding
range (Swairjo et al., 1998). A resultant loss in a hydro-
gen bond due to flap displacement may also be seen
between peptide backbone G51 and carbonyl oxygen of
I50′, which plays a role in stabilizing inhibitor binding
(Swain et al., 1990). Polymorphic variations at position
36, which are seemingly closely related to E35-R57 salt
bridge formation as seen in the C-SA PR, consensus
subtype B PR, and subtype B-MDR PR, may be impli-
cated in drug resistance via effects on flap dynamics.
MD simulations
MD simulations were performed to explore the dynamics
of the flap region as well as the overall flexibility of the
PRs. The root-mean-square fluctuation (RMSF) for each
of the 198 residues of the homodimeric HIV PRs was cal-
culated over the 10 ns MD trajectory (Figure 6(A)). No
significant differences in main chain B-factors between
the C-SA PR and the subtype B PR structures were
observed. Seibold and Cukier (2007) reported that the
D25N mutant exhibited the same dynamic behavior as
the wild-type PR and has no effect on the overall confor-
mational behavior of the flap regions (Seibold & Cukier,
2007). Moreover, as evident from the RMSF calculations
(Figure 6(A)), no noticeable difference in the fluctuation
is observed at positions 25/25′. Therefore, the D25N
mutation does not affect the overall flap flexibility.
The RMSF for the 99 residues of each monomer of
all three PRs shows close similarity over the 10 ns simu-
lation, as is expected for a homodimeric protein. The
residues of the hinge region show high RMSF (residues
35–42 and 57–61) when compared to the rest of the
protein, as can be seen by the peaks in Figure 6(A).
Figure 4. Structural alignment of ribbon representations of the
C-SA PR (green, PDB ID: 3U71), consensus subtype B PR
(cyan, PDB ID: 2PC0), and subtype B-MDR PR (magenta,
PDB ID: 1RP1). The hinge region of each monomer is
indicated in the frames.
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These residues are solvent exposed and are expected to
display high RMSF compared to buried residues such as
the catalytic aspartic acids at position 25 of each mono-
mer. Regions of the C-SA PR (red) and consensus sub-
type B PR (black) that differ significantly in RMSF per
residue are the flap tip (residues 46–54) of the first
monomer and residues 55–75 of the second monomer.
These regions are identical in primary sequence between
the two PRs with the exception of the polymorphism at
position 69, suggesting that the polymorphisms occurring
in the C-SA PR impart local stability changes as well as
changes distal to the sites of polymorphisms.
The open conformation of the HIV-1 PR has been
inferred from NMR (Ishima, Freedberg, Wang, Louis, &
Torchia, 1999) and MD simulation experiments (Scott &
Schiffer, 2000). Both the C-SA PR and consensus sub-
type B PR displayed open flap conformations (12–14Å),
and relaxed to semi-open conformations ( 7Å) for
most of the duration of the simulation, Figure 6(B)
showing the inter-flap distance (Cα I50–Cα I50´) of the
three PRs. Crystal structures of inhibitor bound subtype
B and C PRs display inter-flap distances of 5.86–6.02Å
(Coman et al., 2007; Kempf et al., 1995), representative
of a closed conformation. The semi-open conformations
of the C-SA PR and consensus subtype B PR overlap
with closed inter-flap distances. The subtype B-MDR PR
opens wider than the other PRs for most of the simula-
tion, fluctuating with an inter-flap distance of  9Å in
Figure 5. (A), (B), and (C) show images of the hinge regions of both monomers (left – subunit 1, right – subunit 2) for the C-SA
PR, consensus subtype B PR, and subtype B-MDR PR, respectively. The differing hinge-located residue of each PR is highlighted
(green: isoleucine, cyan: methionine, and magenta: valine); hydrogen bonds are depicted by dashed lines and interatomic distances in
Å are shown.
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its semi-open conformation. Although the inter-flap
distances between the C-SA PR and the consensus sub-
type B PR do not differ greatly for the duration of the
simulation, it is important to note that the C-SA PR
shows greater fluctuation in inter-flap distance in its
semi-open conformation as compared to both subtype B
PRs. At, approximately, all conformations of the C-SA
PR, its flap tips fluctuate within 3Å whereas the flap tips
of the consensus subtype B PR generally fluctuate within
1Å of each other. This difference is highlighted in the
final ns of the simulation where the inter-flap distances
of all three structures coincide and it can be clearly seen
that the inter-flap distance of the C-SA PR fluctuates
between a wider range than both subtype B PRs. This
large fluctuation implies increased flexibility of the flaps
of the C-SA PR in comparison to the subtype B PRs.
Although the subtype B-MDR PR exhibits the E35-R57
salt bridge in both its monomers, it still displays a fair
degree of fluctuation in inter-flap distance and a wider
semi-open conformation for most of the simulation. This
discrepancy is likely due to the M46L and I54V muta-
tions which reduces the bulk around the flap tips and has
been shown to destabilize the flaps and decrease PI bind-
ing (Clemente et al., 2004). As PIs are rigid, they prefer-
entially bind to more closed flap conformations
(Clemente et al., 2004). Once again, this emphasizes the
importance of the E35-R57 salt bridge which we postu-
late stabilizes the hinge region of the PR resulting in
restrained movement of the flap-hinge region of the PR
allowing for more closed flap conformations. In the
C-SA PR, the absence of the salt bridge may allow for
less restricted movement of the flap-hinge region result-
ing in the large fluctuations in the inter-flap distances
seen in the simulation.
The flexible flaps which are found in all aspartyl PRs
are highly conserved in different isolates of HIV-1 and
HIV-2 PRs (Gustchina & Weber, 1991). All isolates of
HIV-1 and HIV-2 PR have a conserved flap tip (Gustchi-
na & Weber, 1991), 47-IGGIGGFI-54, highlighting its
importance in substrate entry and binding. The central
isoleucine surrounded by two glycine residues on either
side confers flexibility to the flaps, in order for them to
adapt to the asymmetry in the substrate sequence (Gust-
china & Weber, 1991; Prabu-Jeyabalan, Nalivaika, &
Schiffer, 2000). Importantly, I50 and I50′ have been
shown to be involved in water-mediated hydrogen bonds
with peptide substrate (Prabu-Jeyabalan et al., 2000).
Although increased flexibility of the flaps could result in
increased substrate entry, interaction of substrate/inhibitor
with PR is likely to be of lower affinity. This reduced
affinity may be seen as the flaps which are involved in
vital hydrogen bonds with substrate/inhibitor, may be
displaced to a level that weakens or causes loss of these
hydrogen bonds. Previously reported inhibition data
shows that the C-SA PR displays reduced affinity for
FDA-approved PR inhibitors compared to the subtype B
PR, with the C-SA PR displaying the greatest reduction
for the inhibitor ritonavir (Mosebi et al., 2008;
Velázquez-Campoy et al., 2003). The reduced affinity for
PR inhibitors may be a result of increased flexibility of
the flaps due to the absence of the E35-R57 salt bridge
in the hinge region, as suggested in this study.
Conclusion
The absence of the E35-R57 salt bridge in the C-SA PR
results in increased flexibility of the flaps of the enzyme,
suggested by the large fluctuations in inter-flap distances
during simulation studies. We propose that this increased
flexibility is a result of less restrained movement of the
Figure 6. (A) RMSF of each residue and (B) distance
between the flap tips (Cα I50 and Cα I50′) over the 10 ns
simulation for the structures under investigation; red (C-SA PR,
PDB ID: 3U71), black (consensus subtype B PR, PDB ID:
2PC0), and blue (subtype B-MDR PR, PDB ID: 1RPI).
Magenta and blue bars in (A) correspond to the hinge and flap
region, respectively.
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flap-hinge region. The increased flap flexibility likely
contributes to the increased drug resistance seen in the
C-SA PR (Mosebi et al., 2008; Velázquez-Campoy et al.,
2003) as suitable conformations of the flaps are vital for
effective drug binding.
The polymorphisms between HIV-1 subtype B PR
and the C-SA PR do not impact on the overall structure.
However, we have identified dynamic differences between
the C-SA PR and subtype B PRs. This is the first study to
report on the crystal structure of the C-SA PR which is an
epidemiologically relevant PR. The crystal structure of
the C-SA PR will serve as a foundation to improve the
rational design of PIs which will have a greater impact on
antiretroviral chemotherapy in sub-Saharan Africa.
Abbreviations
PR Protease
PI PR inhibitor
C-SA PR South African subtype C PR
PDB Protein data bank
MD Molecular dynamics
RMSF Root-mean-square fluctuation
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 Abstract 
 
Since its identification, HIV continues to have a detrimental impact on the lives of millions of 
people throughout the world. The protease (PR) of HIV is a major target in antiviral treatment. 
The South African HIV-1 subtype C protease (C-SA PR) displays weaker binding affinity for 
some clinically-approved protease inhibitors in comparison to the HIV-1 subtype B protease. 
The heavy HIV burden in sub-Saharan Africa, where subtype C HIV-1 predominates, makes this 
disparity a topic of great interest. In light of this, the enzyme activity and affinity of protease 
inhibitors for the subtype B and C-SA PRs were determined. The relative vitality, indicating the 
selective advantage of polymorphisms, of the C-SA PR relative to the subtype B PR in the 
presence of ritonavir and darunavir was 4-fold and 10-fold greater, respectively. Dynamic 
differences that contribute to the reduced drug susceptibility of the C-SA PR were investigated 
by performing hydrogen/deuterium exchange-mass spectrometry (HDX-MS) on the unbound 
subtype B and C-SA PRs. The reduced propensity to form the E35-R57 salt bridge and 
alterations in the hydrophobic core of the C-SA PR is proposed to affect the anchoring of the 
flexible flaps resulting in an increased proportion of the fully-open flap conformation. HDX-MS 
data showed that the N-terminus of both PRs appears to be less stable than the C-terminus of the 
PRs, thus rationalising the increased efficacy of dimerisation inhibitors targeted toward the C-
terminus of HIV PRs. This is the first known report on HIV protease dynamics using HDX-MS.  
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 Introduction  
 
Human immunodeficiency virus (HIV) infections are a global health and socio-economic 
challenge with approximately 35 million people living with the virus in 2012 [1]. Disturbingly, ~ 
70% of these people reside in sub-Saharan Africa and HIV-1 subtype C is the most prevalent 
subtype in this region and globally [1, 2]. In South Africa, an estimated 6.1 million people (~ 
12% of the total population) are living with HIV [1]. The homodimeric HIV protease (PR) is a 
major drug candidate because it has a central role in the life cycle of the virus. The first-line 
antiretroviral therapy (ART) guidelines for adults and adolescents include the use of two 
nucleoside reverse transcriptase inhibitors in combination with one non-nucleoside reverse 
transcriptase inhibitor [3]. Second-line ART may proceed upon failure of the first-line ART 
regimen in an individual. The preferred protease inhibitors (PIs) in second-line ART for adults 
and adolescents are atazanavir, darunavir or lopinavir in combination with the PI booster, 
ritonavir [3].  
 
The present study investigates the differences in binding affinity to clinically-used PIs and the 
dynamic differences of the consensus HIV-1 subtype B protease (subtype B PR) and South 
African HIV-1 subtype C protease (C-SA PR) which is effectively the consensus HIV-1 subtype 
C protease (Los Alamos HIV sequence database, http://www.hiv.lanl.gov/). Importantly, the C-
SA PR differs by eight amino acids per PR monomer to the subtype B PR (Fig. 1). FDA-
approved PIs have been designed against the HIV-1 subtype B PR which predominates in North 
America and Europe and is less prevalent globally [2]. When comparing the C-SA PR to the 
subtype B PR, the following polymorphisms are observed: 3 situated in the fulcrum region 
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 (T12S, I15V and L19I), 2 in the hinge region (M36I and R41K), 1 in the 60’s loop (H69K), 1 in 
the 80’s loop (L89M) and 1 at the end of the single α-helix of each monomer (I93L) [4]. These 
polymorphisms represent non-active site mutations and therefore, do not directly affect inhibitor 
binding [4]. 
 
Previous comparison of PI binding to the C-SA PR showed a ~ 8-fold weaker affinity for 
lopinavir than the subtype B PR [5]. Only recently has the crystal structure of the C-SA PR been 
elucidated [6], whereas, the structure of the subtype B PR has been well studied. A structural 
comparison of the PRs does not definitively provide a clear basis for the differences in drug 
binding. Molecular dynamics (MD) simulations showed that the inter-flap distance (distance 
between Cα of I50 on adjacent monomers) of the subtype B PR appeared to fluctuate within a 1 
Å distance, whereas, that of the C-SA PR fluctuated within 3 Å, implying altered flexibility of 
the flap tips (residues at positions 46–54) of the C-SA PR [6]. Increased flap flexibility may 
result in reduced binding affinity to PIs as the flap tips are involved in water-mediated 
interactions with substrates/inhibitors [7]. Distance measurements using spin-labelled pulsed 
electron paramagnetic resonance (EPR) spectroscopy, displayed an increased proportion of the 
curled and fully-open conformations (Fig. 2C) of the flaps in the subtype C PR population 
relative to other HIV-1 PRs [8]. No x-ray diffracted structural data is available for the curled and 
fully-open conformers. The curled conformer is described by pronounced curling of the flap tips 
(residue positions 48–52) [9]. The fully-open conformer also displays flap tip curling, 
accompanied by upward and outward displacement of the flap-hinge region from the active site 
[10]. The majority of C-SA PR molecules exist in the semi-open conformation in solution (Fig. 
2B) [8, 10-12]; however, there is a definite shift in the equilibrium between semi-open and other 
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 flap conformers. At baseline, an ensemble of semi-open conformers may exist. These semi-open 
conformers may directly interchange with closed conformers (Fig. 2A). Structural and PR 
dynamics studies indicate that the curled conformer may be an intermediate state which allows 
for the formation of the fully-open conformer [9, 11, 13]. Entry of a substrate or inhibitor to the 
active site of the PR requires substantial movement of the flaps (~ 15 Å from their position in the 
closed conformer) [14]. Structure-based calculations reveal that semi-open conformers do not 
permit the entry of substrate/inhibitor to the active site [15]. Therefore, it is accepted that only 
the fully-open conformation allows for substrate/inhibitor binding. Complete flap opening occurs 
through concerted downward movement of the hinge (residue positions 35–42 and 57–61), 
cantilever (residue positions 62–78) and fulcrum (residue positions 10–23) regions (Fig. 1) 
which results in the upward and outward motion of the flaps (Fig. 2C) [10]. The vast majority of 
studies measuring PR dynamics are investigated using MD simulations. MD simulation results 
require careful attention for correct interpretation; however, are useful when complemented with 
experimental data. Other analyses of PR dynamics were investigated using nuclear magnetic 
resonance (NMR) [11, 12, 16], which is limited by the modest sensitivity of the technique, and 
spin-labelled pulsed EPR spectroscopy [8, 17], which was used to exclusively measure distances 
between flap residues. Combined EPR spectroscopy and NMR experiments have identified and 
verified the population of flap conformers in the apo-state and during inhibitor binding for the 
subtype B and C HIV-1 PRs [18]. However, these experiments did not fully elucidate the 
mechanism for the reduced drug susceptibility displayed by the subtype C HIV-1 PR. Here we 
probed the mechanism for the altered flap flexibility and reduced susceptibility of the C-SA PR 
to PIs by performing hydrogen/deuterium exchange-mass spectrometry (HDX-MS) on apo-
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 subtype B and apo-C-SA PRs. To our knowledge, this is the first HDX-MS study performed on 
HIV-1 proteases.  
 
Results 
 
C-SA PR viral fitness 
 
Following expression and purification, the subtype B and C-SA PRs were > 99% pure. The HIV-
1 PR fluorogenic substrate (Abz-Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2), which mimics the 
capsid/p2 cleavage site in the HIV-1 Gag polyprotein, was used to determine the kinetic 
parameters of the PR-substrate reaction (Table 1). Both PRs display comparable kinetic 
parameters; however, the C-SA PR shows a two-fold increase in the turnover of substrate, as 
seen by a higher kcat value (Table 1).  
 
Inhibition constants (Ki) of PIs for the subtype B and C-SA PRs were determined from their 
respective IC50 determinations (Table 2). The thermodynamic parameters (ΔG, ΔH, –TΔS, Kd 
and n), determined by ITC, describe the overall energetic contribution to the interaction. For all 
ITC experiments, a stoichiometry value (n) of > 0.95 was achieved. Binding thermodynamics of 
acetyl-pepstatin, a substrate analogue, is similar for both PRs. Displacement titration ITC was 
employed to improve the accuracy of the determined Kd values, the affinity of the FDA-approved 
PIs for both the subtype B [19, 20] and C-SA PRs were in the nM–pM range (Table 2). The 
binding affinities of the PIs for both PRs were also compared using the Ki and relative vitality 
values. Atazanavir displays a similar affinity for the subtype B and C-SA PRs. Darunavir shows 
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 a 7-fold reduced affinity for the C-SA PR compared to the subtype B PR. The binding of 
darunavir to both PRs is enthalpically driven; however, binding to the C-SA PR displayed an 
unfavourable entropy change (-TΔS > 0) which contributes to the reduced affinity. The C-SA PR 
displays a relative vitality of ~ 4 and ~ 10 in the presence of ritonavir and darunavir, 
respectively. This suggests that subtype C HIV-1 may have a greater capacity to replicate in the 
presence of ritonavir and darunavir when compared to subtype B HIV-1. Therefore, the C-SA PR 
displays reduced drug susceptibility to ritonavir and darunavir in comparison to the subtype B 
PR. 
 
Amide hydrogen-deuterium exchange 
 
Two aspartyl proteases, porcine pepsin and protease XIII from Aspergillus saitoi, were tested for 
optimum cleavage of the HIV-1 PRs following deuterium labelling. Due to the pH range of their 
optimal activity, aspartyl proteases are the only enzymes used for fragmentation during a HDX-
MS experiment. The competitive inhibition of pepsin by FDA-approved HIV-1 PIs has been 
described previously [21]. Ki values of 0.6 μM and 2.1 μM were obtained previously for binding 
of porcine pepsin to ritonavir and darunavir, respectively [21]. In the present study, attempts to 
determine HDX in the presence of PIs were unsuccessful. After optimisation, cleavage of the 
HIV-1 PRs in the presence of HIV-1 PIs by both pepsin and protease XIII was poor, producing 
large amounts of undigested PR and only 5 and 2 detected peptide fragments, respectively. 
Therefore, HDX-MS analysis was limited to the unbound form of the PRs. 
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 The conformational dynamics of the apo-PRs were measured by detecting the exchange of 
backbone amide hydrogen atoms with deuterium atoms in solution. In this study, amide 
hydrogen/deuterium exchange (HDX) was detected via mass spectrometry. HDX was measured 
at pH 5.0 in accordance with the activity and inhibition assays. The catalytic dyad (D25 and 
D25ʹ) of HIV-1 PR is monoprotonated at pH 5–6 and the PR displays maximal activity and 
stability in this pH range [22]. At pH 7.0, the catalytic dyad loses its proton and becomes more 
unstable [23]. Measuring HDX at pH 5.0 also enables the detection of amide protons that may 
exchange too fast at pH 7.0. At pH > 4.0, HDX is catalysed by direct attack and H-bonding of 
OD
-
 to the exchangeable proton, thus, HDX at pH 5.0 reports on PR dynamics [24-26]. The 
HDX reaction was quenched at several time points (10 s–1 hr) to map fast as well as 
intermediate exchanging regions of the PRs. During analysis, 35 peptides derived from the 
subtype B PR and 41 peptides from the C-SA PR were used to provide complete coverage of 
both PRs. Thirty-four of these peptides were in common to both PRs. The first and second amide 
protons of each peptide are unable to retain deuterium due to cleavage of the PRs by pepsin and 
binding of the resultant peptides to the C18 reversed-phase column [27]. Proline residues do not 
possess an amide hydrogen and HDX at these residues along with the first and second residues of 
each peptide are not measured. The heat maps in Figure 3 display the percentage of deuteration 
across all regions of the PRs barring the residues at positions 1–2. Proteins exhibit highly mobile 
behaviour in solution. Exchange in a folded protein is believed to occur through low amplitude 
atomic motions, of ~ 1 Å, which are sufficient to allow for diffusion of D2O and OD
-
 to 
backbone amide linkages [28, 29]. Thus, there is a steady increase in the percentage of 
deuteration at various regions of the PRs with increasing incubation time (Fig. 3).  
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 The amplitude and rates of HDX in peptides covering the regions near polymorphic sites were 
measured (Table 3). During analysis, fast and intermediate exchange rates were determined and 
are similar in the respective peptides of both PRs. Engen et al. have proposed that amide protons 
exchanging at very fast rates (i.e. unprotected and solvent exposed) must exchange from the 
folded form of the protein [30]. Amide protons exchanging at fast to slow rates require local 
structural fluctuations prior to exchange. In peptides 13–23, 34–53 and 64–90 the number of 
amide protons with very fast and/or fast exchange rates is less in the C-SA PR than in the 
subtype B PR. The number of amide protons in these peptides exhibiting intermediate exchange 
rates is greater in the C-SA PR. The total number of amide protons exchanged is similar in both 
PRs after 1 hour. Therefore, the number of slow exchanging amide protons in these peptides is 
similar and differences are restricted to the number of fast and intermediate exchanging amide 
protons. The regions of HIV-1 PR covered by these peptides are displayed in Figure 4. 
Deuterium incorporation plots show the number of deuterons incorporated into the relevant 
peptides with respect to the incubation time. Differences in deuterium incorporation at the N- 
and C- termini are highlighted in Table 4. Exchange at the N-terminus of both PRs is similar. 
The C-SA PR shows increased dynamics at C95 and T96 in comparison to the subtype B PR.  
 
Discussion 
 
Dynamics of the HIV-1 PR 
 
Heat maps (Fig. 3) show results as percentage deuteration, thereby, normalising the deuterium 
incorporation in the measured peptides and allowing for a direct comparison of different regions 
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 of the HIV-1 PR. Increased spatial resolution in the heat maps is allowed for by peptide overlap.  
Improved spatial resolution for the C-SA PR is evident in parts of the heat maps due to increased 
peptide detection and overlap. Both PRs display similar exchange profiles across different 
regions. Residues around the active site triplet (D25, T26 and G27) display slow deuterium 
incorporation in comparison to the other regions of the PRs. These residues are positioned deep 
within the active site cavity. Slow exchange is expected here due to low solvent accessibility and 
a complex network of interactions around the active site core. The flap tips (residues at positions 
49–53) are the regions of the PRs that display the fastest deuterium incorporation. The flaps are 
completely solvent exposed and highly mobile regions of the PRs. The reported HDX-MS profile 
of HIV-1 PR is in agreement with previous NMR data [11, 12, 16]. 
 
HDX in macromolecules resulting from local unfolding events may either occur via a correlated 
(EX1) or uncorrelated (EX2) mechanism [26, 31, 32]. HDX in the subtype B and C-SA PRs 
displays EX2 kinetics indicated by the single binomial isotopic distribution of the mass spectra in 
the current study [33]. This uncorrelated exchange mechanism may be well-illustrated by HDX 
at α-helices [34]. As seen in Figure 3, exchange at residues in the single α-helix of the HIV-1 PR 
(residues at positions 87–93) occurs independently of each other. HDX via the EX2 mechanism 
suggests that segments of the PRs must unfold and refold many times before exchange within it 
is complete [26, 31, 32].      
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 Comparison of conformational stability between the subtype B and C-SA proteases 
 
Previous differential scanning calorimetry studies showed that the overall conformational 
stability of the C-SA PR was slightly reduced in comparison to the subtype B PR [5]. In the 
current study, subtle differences in stability at different regions of the PRs were observed. In 
most peptides, the number of amide protons exchanging at fast rates increased by ~ 1 amide 
proton in the subtype B PR relative to the C-SA PR. This may imply that the C-SA PR is more 
stable than the subtype B PR. However, residues at the C-terminus of the C-SA PR appear to be 
more dynamic (Table 4). Thermodynamic analyses showed that the N- and C-terminal 
antiparallel β-sheet contributes 75% to the total Gibbs energy [35]. A more dynamic C-terminus 
will affect the stability of the terminal β-sheet and greatly impact the overall conformational 
stability. Salt bridges also affect the conformational stability of a macromolecule [36, 37]. 
Crystal structure analysis shows that the C-SA PR lacks the K20-E34 and E35-R57 salt bridges 
relative to the subtype B PR in their crystalline forms. Therefore, the reduced number of ionic 
interactions and a less stable terminal β-sheet evident in the C-SA PR are major determinants for 
the apparent overall reduced conformational stability of the C-SA PR.   
 
Dynamics around the polymorphic sites 
 
Figure 1 shows the position of the eight polymorphisms in the subtype B and C-SA PRs. As 
mentioned previously, 3 polymorphic sites are situated in the fulcrum region (T12S, I15V and 
L19I), 2 in the hinge region (M36I and R41K), 1 in the 60’s loop (H69K), 1 in the 80’s loop 
(L89M) and 1 at the end of the single α-helix of each monomer (I93L). For peptides 13–23, 34–
53
 53 and 64–90 (Fig. 4) subtle differences in deuterium incorporation between the subtypes are 
evident. In all of the aforementioned peptides covering the 60’s and 80’s loops, the fulcrum 
region and the flap-hinge region, there is a reduction in the number of very fast and/or fast 
exchanging amide protons (12 > k > 0.1 min
-1
) and a concomitant increase in the number of 
intermediate exchanging amide protons (0.1 > k > 0.01 min
-1
) in the C-SA PR (Table 3). These 
results indicate that these regions of the C-SA PR are more stable than that of the subtype B PR. 
 
The differences observed in peptides 13–23 (covering the fulcrum region), 34–53 (covering the 
hinge region) and 64–90 are explained in part by the varying preference of flap conformations 
between the PRs. Distance measurements during pulsed EPR experiments showed that the total 
population of the fully-open conformer increased by 23% with a concomitant decrease by 15% in 
the total population of semi-open conformers in the subtype C PR relative to the subtype B PR. 
Complete flap opening occurs through concerted downward movement of the hinge (residue 
positions 35–42 and 57–61), cantilever (residue positions 62–78) and fulcrum (residue positions 
10–23) regions which results in the upward and outward motion of the flaps (Fig. 2C) [10]. The 
cantilever region is covered by peptide 64–76 in the current study (Table 3). Slightly increased 
dynamics is also displayed in the cantilever region of the subtype B PR. In the fully-open 
conformer, the parts of the hinge and cantilever regions are anchored in the hydrophobic core of 
the PR [38]. Therefore, parts of the hinge, cantilever and fulcrum regions are likely stabilised in 
the fully-open conformer. This detail may explain in part the reduced dynamics at peptides 13–
23, 34–53 and 64–90 in the C-SA PR.  
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 Dynamics at the flap tips  
 
A recent simulation study indicated altered flap tip flexibility between the apo-form of the C-SA 
PR and subtype B PR on a picosecond to nanosecond time scale [6]. The C-SA PR displayed a 
wider range of open conformers than the subtype B PR. These findings hint at an altered stability 
around the flap tips of the C-SA PR which allow for the variation in open conformers. Similar to 
the thermodynamic data reported here (Table 2), HIV-1 PRs with flap tip mutations displayed 
reduced binding entropy in comparison to wild-type PR, which is compensated for by enhanced 
binding enthalpy during atazanavir and darunavir binding [39]. Only subtle packing 
rearrangements around the flap region and inhibitors were identified in the inhibitor-bound 
structures of these mutants [39]. Observed entropic effects during inhibitor binding to PRs with 
flap tip mutations as well as the C-SA PR indicate changes in flap flexibility and/or solvation in 
comparison to the wild-type subtype B PR. Because the C-SA PR does not possess any flap tip 
mutations, increased flexibility of the flap tips is unexpected. As mentioned, the C-SA PR has a 
greater preference for the fully-open conformation than other HIV-1 subtypes including multi-
drug resistant variants [8]. An increased proportion of fully-open conformers are also evident in 
C-SA PR in comparison to the subtype B PR when saturated with atazanavir and darunavir [18]. 
Fully-open conformers allow access of more ordered solvent to the active site than semi-open 
conformers. These findings may explain the less favourable binding entropy displayed by the C-
SA PR during binding to atazanavir and darunavir (Table 2).  
 
Data for peptide 47–53 measures deuterium incorporation at backbone amides for residues at 
positions 49–53 (flap tips). Importantly, the flap tips are solvent exposed in all flap conformers. 
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 Therefore, HDX at the flap tips are mostly dependent on local atomic fluctuations which reduce 
the number of protected amide protons (amide protons involved in interactions) rather than an 
increase in solvent accessibility to unprotected amide protons. The C-SA PR displays a reduction 
in the number of very fast exchanging amide protons (Table 3) which reflect the amides that are 
available for exchange at baseline. The C-SA PR also displays a slight reduction in the number 
of fast exchanging amide protons. This difference is explained in part by the increase in the 
proportion of curled conformers in the C-SA PR population in comparison to that of the subtype 
B PR. Distance measurements during pulsed EPR experiments showed that the total population 
of the curled conformer increased by 8% in the subtype C PR relative to the subtype B PR [8]. 
Importantly, during flap tip curling I50 of each monomer is buried and stabilised by hydrophobic 
contacts with I47, I54, P79 and P81 [9]. This affects HDX-MS data, as more interactions need to 
be broken in a curled conformation before amide proton exchange proceeds relative to the semi-
open conformation. Moderate fluctuations of > 3 Å between interacting groups are required for 
OD
-
 catalyst attack when exchangeable amide protons are involved in interactions [40]. In a 
similar manner, MD simulation data suggest that the fully-open conformer displays curling of the 
flap tips [10]. As mentioned, the C-SA displays a greater population of fully-open conformers in 
comparison to the subtype B PR. Therefore, the increased proportion of fully-open conformers in 
the C-SA PR population may also account for the reduction in fast exchanging amide protons 
(Table 3) in the flap tips of the C-SA PR. When dealing with multiple conformers, it is important 
that data has been standardised. Importantly, all HDX-MS data was derived from subtype B and 
C-SA PR solutions with an active site concentration of greater than 95% (see methods; active 
site determination). This active concentration illustrates the population of PRs in solution that 
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 display an active conformation. Therefore, a fair comparison of PR dynamics may be made 
based on differences in flap conformers between the subtype B and C-SA PRs.  
 
Effect of secondary resistance mutations on flap movement 
 
Globally, the structure of the subtype B and C-SA PRs do not differ. Detailed comparison of the 
structures revealed no significant differences at any of the polymorphic sites with the exception 
of the residue at position 36. Subtle differences are evident in the hinge region (residue positions 
35–42 and 57–61) of the PRs (Fig. 5) [6]. The hinge region is implicated in the control of the 
flexible flaps of the PR and the flap tips are involved in water-mediated contacts with 
substrates/inhibitors. Importantly, M36 in the subtype B PR shows no exchange over all time 
points, whereas, I36 in the C-SA PR has exchanged its amide hydrogen at 10 seconds (Fig. 3). 
This supports the crystallographic evidence which shows the amide group of M36 in the subtype 
B PR interacting with the E35 side chain, thereby, facilitating the E35-R57 salt bridge (Fig. 5A) 
which is the only salt bridge in the flap-hinge region. I36 of the C-SA PR is not involved in a 
similar interaction (allowing for exchange of its amide hydrogen). Therefore, the C-SA PR has a 
reduced propensity to form the E35-R57 salt bridge likely contributing to altered flap dynamics. 
 
The M36I mutation is considered to be a secondary drug resistance mutation. The M36I mutation 
is the only polymorphic mutation in the C-SA PR which is associated with drug resistance to 
most of the FDA-approved PIs in combination with ritonavir (Stanford University HIV drug 
resistance database [41]). This mutation is associated with virologic failure or reduced virologic 
response to atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, saquinavir and tipranavir 
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 in combination with ritonavir [42-49]. Mutations at residue position 89 are associated with 
virologic failure to darunavir and tipranavir in combination with ritonavir [44, 50] and mutations 
at residue position 93 are associated with virologic failure to saquinavir in combination of 
ritonavir [42, 49]. Although the other polymorphisms inherent in the C-SA PR have not been 
associated with virologic failure in clinical studies, they may still contribute to the observed 
reduced drug susceptibility of the C-SA PR.  
 
The importance of other polymorphisms inherent to the C-SA PR in relation to reduced drug 
susceptibility may be explained through the process of hydrophobic sliding [38]. A molecular 
dynamics simulation study identified hydrophobic residues whose side chains were buried for the 
majority of the simulation [38]. These 19 residues per monomer are referred to as the 
hydrophobic core of the PR (Fig. 6) [38]. Although the residue at position 19 was not identified 
as part of the hydrophobic core, the L19I mutation may contribute to rearrangement of 
interactions in the hydrophobic core. Therefore, L/I19 was included in the hydrophobic core in 
the current study. In the unliganded PR, rearrangement of interactions in the hydrophobic core 
facilitate flap movement upward and outward from the active site [38]. Seven isoleucines per 
monomer are present in the core and may provide increased flexibility because they can exist in 
more possible conformations than other hydrophobic residues [38]. In the crystal structure of the 
subtype B PR, I15 makes van der Waal contacts with L33, M36 and L38 which form part of a 
loop in the hinge region. I15 also makes van der Waals contacts with I62, I64 and V75 in the 
cantilever region comprising residues at positions 62–78 which is closely associated with the 
hinge region. During flap movement, the loops (hinge and cantilever regions) slide over I15 and 
the contacts that are lost by I15 are gained by I13 (both I13 and I15 forming part of the fulcrum 
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 region) [38]. Interaction of these loops with the hydrophobic core allow for anchoring of the 
flaps. When the loops slide over residues of the hydrophobic core, wider opening of the flaps 
occur. Cross-linking studies have confirmed that altered flexibility in the hydrophobic core 
modulates PR activity and movement of the core is required for function [51]. Rearrangement of 
the hydrophobic core residues and exchange of one set of hydrophobic contacts for another likely 
result in modest energetic penalties [38].  
 
In the C-SA PR, I15V, L19I, M36I, L89M and I93L polymorphisms occur in the hydrophobic 
core. These polymorphisms may alter the network of hydrophobic contacts in the core. In the 
crystal structure of the C-SA PR, V15 does not interact with V75. However, this interaction may 
occur during flap movement. It is evident from the crystal structures that these polymorphisms 
bring about slight changes in the complex network of hydrophobic interactions. Due to its high 
incidence in drug-resistant isolates, the M36I mutation likely contributes the greatest to 
differences in flap dynamics between the PRs. Rotation of this I36 through different rotamers 
may assist in sliding over other hydrophobic residues.  Only subtle differences in the 
hydrophobic core are evident between the crystal structures of the subtype B and C-SA PRs. 
Similarly, the HIV-1 A_E variant which has polymorphisms in the hydrophobic core does not 
display major structural differences in this region relative to the subtype B PR [52]. Analysis of 
the dynamics of the hydrophobic core is limited because residues in the core are disconnected in 
the primary structure of the HIV-1 PR. Residue-level resolution of hydrophobic core residues 
was not obtained in this study. However, the dynamic nature of the peptides covering the hinge 
loop and cantilever loop which anchor the flaps were measured. As mentioned previously, the 
hinge region of the C-SA PR undergoes reduced rates of amide hydrogen exchange in 
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 comparison to the subtype B PR. For peptide 64–76 (covering part of the cantilever region), a 
slight reduction in fast exchanging amide protons (meaning more protected amide protons) is 
observed in the C-SA PR (Table 3). These results indicate that the network of interactions in the 
hydrophobic core of the C-SA PR may be altered. The hinge, cantilever and fulcrum regions 
which are important for flap opening display increased stability in the C-SA PR and may 
stabilise the wide range of fully-open conformers exhibited by the C-SA PR. 
 
Preferential targeting of the C-terminus to prevent dimerisation 
 
The N-terminus (positions 1–5) and C-terminus (positions 95–99) of HIV-1 PRs are pivotal in 
dimer stability; structure-based thermodynamic analyses showed that the N- and C-termini 
antiparallel β-sheet contributes ~ 75% to the total Gibbs energy [35]. Thermodynamic and 
structural analyses of recombinant HIV-1 PRs with a short segment of the transframe region 
tethered to the N-terminus of the PR, displayed significantly reduced thermal stability compared 
to wild-type HIV-1 PR and crystallographic data showed evidence of random coils at the N-
terminus [53]. Recombinant HIV-1 PR with a short segment of reverse transcriptase tethered to 
the C-terminus showed no significant reduction in thermal stability, implying increased stability 
of the C-terminus relative to the N-terminus [53]. A similar result is seen in the HDX-MS 
experiment for both the subtype B and C-SA PRs (Table 4).  
 
Due to cleavage of the PRs by pepsin and binding of the resultant peptides to the C18 reversed-
phase column [27], the HDX data for peptide 1–5 reports on the peptide-amide linkages at 
residue positions 3–5 and data for peptide 95–99 reports on the peptide-amide linkages at residue 
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 positions 97–99. The amide groups of L97 and F99 participate in hydrogen bonds with the N-
terminus of the adjacent subunit; meaning, interactions need to be broken for HDX to proceed. 
After 1 minute of incubation in deuterium oxide, both PRs display low levels of deuterium 
incorporation at the N- and C-termini (< 0.5 deuterons). After 1 hour of incubation, the 
differences are more pronounced; more than 1.6 amide protons are exchanged in peptide 1–5 
(reporting on I3, T4 and L5) and less than 1 proton is exchanged in peptide 95–99 (reporting on 
L97, N98 and F99) in both PRs. Therefore, only a fraction of the PRs in solution exchange an 
amide proton after 1 hour of incubation at their final 3 residues (Table 4). Rates of HDX in this 
region reflect the internal motions of the β-sheet formed by the N- and the C-termini. Therefore, 
the N-terminus of both PRs is seemingly more dynamic than the C-terminus. Targeting the 
residues at positions 1–5 and 95–99 in HIV-1 and HIV-2 PRs with complementary synthetic 
peptides has shown inhibitory potential [54]. Inhibitors targeted to the C-terminus alone 
displayed greater potency than inhibitors targeted to the N-terminus or both ends of the PR [54]. 
Drug resistance to currently available PIs are attributed to active site and flap-hinge region 
mutations. Dimerisation inhibitors attempt to solve this complication by targeting an alternative 
site. 
 
Using overlapping peptides, deuterium incorporation of other C-terminal amide protons (C95 
and T96) may be determined. Calculating the difference in deuterium incorporation between 
peptides 77–99 and 77–94 allows for HDX measurement at residue positions 95–99. Subtracting 
the known incorporation at residue positions 97–99 from the calculated 95–99 allows for 
resolution of C95 and T96 (Table 4). Differences in deuterium incorporation at peptide 77–94 
between the PRs is evident from 5 minutes of incubation and is most pronounced after 1 hour of 
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 incubation. Therefore, detailed analysis of deuterium incorporation was performed using data 
resulting from 1 hour of incubation. Analysis of exchange at C95 and T96 shows that ~ 0.6 
amide protons have exchanged in the subtype B PR, whereas, these amide protons are fully 
exchanged (2 amide protons) in the C-SA PR. This suggests that the C-terminal residues, C95 
and T96, are more dynamic in the C-SA PR. Therefore, these residues may contribute less to the 
stability of the N- and C-termini β-sheet than other C-terminal residues. Mutation of the ultimate 
amino acid in the HIV-1 PR sequence, phenylalanine, to an alanine was shown to reduce the β-
sheet content of the PR and disrupt dimerisation which results in complete loss of activity [55]. 
Contacts made by F99 with neighbouring residues are shown in Figure 7. F99 is central to the 
large network of interactions present in the ‘lock-and-key’ motif (Fig. 7). Therefore, the 
importance of the C-terminus for correct folding of the PR and its increased stability in 
comparison to the N-terminus, make the C-terminus, particularly F99, a preferred target for 
antiviral therapy. 
 
This study represents the first known report of amide hydrogen/deuterium exchange-mass 
spectrometry performed on HIV PR. The C-SA PR displays weaker binding to clinically used 
PIs than the subtype B PR. The C-SA PR has an increased propensity to exist in a fully-open 
conformation (Fig. 2C) [8] and displays a wider range of open conformers than the subtype B PR 
[56]. Altered interactions in the hydrophobic core of the C-SA PR likely contribute to the 
difference in flap ensembles. Polymorphisms in the C-SA PR alter the complex network of 
interactions in the hydrophobic core thus favouring the formation and increasing the stability of 
the fully-open conformer in comparison to the subtype B PR. Importantly, polymorphisms in the 
C-SA PR conserve hydrophobic residues but may alter the anchorage of flaps through altered 
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 hydrophobic sliding. The reduced propensity to form the E35-R57 salt bridge in the C-SA PR in 
combination with altered dynamics at the hinge, cantilever and fulcrum regions contribute to the 
altered anchorage of the flaps and a shift in the equilibrium between semi-open (Fig. 2B) and 
fully-open conformers (Fig. 2C). Because the C-SA PR displays reduced drug susceptibility and 
similar catalytic efficiency in comparison to the subtype B PR, the increased stability of the 
fulcrum, hinge and cantilever regions leading to the shift in flap conformers preferentially affects 
inhibitor binding over substrate binding. The increase in substrate turnover (Table 1) for the C-
SA PR may be explained by its increased proportion of the fully-open conformer when compared 
to the subtype B PR. Substrate processing is only allowed following full opening of the PR flaps. 
This highlights the need to further characterise the fully-open conformer which is a viable target 
for drug design because this conformer is a prerequisite for PR function. Furthermore, the N-
terminus of both PRs appears to be more dynamic than the C-terminus of the PRs, thereby, 
substantiating the targeting of the C-terminus, particularly F99, for the development of 
dimerisation inhibitors.  
 
Materials and Methods 
 
Expression and purification 
 
Escherichia coli BL21 (DE3) pLysS cells were transformed with the pET-11b plasmid encoding 
either the subtype B or C-SA PR insert. The consensus C-SA PR (wild-type) sequence data were 
obtained from Prof Lynn Morris (AIDS Virus Research Unit, National Institute of 
Communicable Diseases, South Africa). A Q7K point mutation was introduced in the PR 
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 sequences by site-directed mutagenesis using the QuikChange® method (Stratagene, La Jolla, 
CA, USA) to reduce PR autocatalysis [57]. 
 
Expression and purification of the PRs were performed as previously described [6]. Briefly, 
transformed cells were induced to over-express the PRs as inclusion bodies using isopropyl-β-D-
thiogalactopyranoside [58]. Inclusion bodies were solubilised using 8 M urea and refolded by 
dialysis into a buffer containing 10 mM sodium acetate, 2 mM dithiothreitol and 0.02% sodium 
azide (pH 5.0). The PRs were purified using CM-Sepharose cation exchange resin, with a 0–1 M 
NaCl gradient elution. The PRs were dialysed into 10 mM sodium acetate, 2 mM dithiothreitol 
and 0.02% sodium azide (pH 5.0) for storage and were resolved on a 10% tricine-SDS 
polyacrylamide gel to evaluate the purity of the proteins [59, 60]. 
 
Active site determination 
 
The percentage of active enzyme in the PR preparations was investigated using isothermal 
titration calorimetry (ITC). Active site determinations were performed at 20 °C using a VP-ITC 
microcalorimeter (MicroCal Inc.). Acetyl-pepstatin (Bachem), a well-known aspartyl protease 
inhibitor, was titrated into the sample cell containing the PR. Saturation of the PRs was achieved 
during titrations using 200 µM acetyl-pepstatin, 10.59 µM subtype B PR and 15.50 µM C-SA 
PR. Calorimetric data were fit using the Origin 7.0 software package. The percentage of active 
sites was determined from the stoichiometry value. 
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 Steady-state and inhibition kinetics 
 
Kinetic parameters, KM, kcat and kcat/KM, were determined in separate experiments following 
hydrolysis of the HIV-1 PR fluorogenic substrate (Abz-Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-
NH2). An active enzyme concentration of 30–50 nM and a substrate concentration ranging 5–200 
µM and 3–10 µM were used to determine KM and kcat/KM, respectively. Varying amounts of 
enzyme (1–10 pmole) were used with a constant substrate concentration (50 µM) for kcat 
determination.  
 
The FDA-approved drugs competitively inhibit HIV PR with dissociation constants within the 
nM–pM range. Inhibition constants (Ki) of atazanavir, darunavir and ritonavir (NIH AIDS 
Reagent Program) were determined using the following equation for tight-binding inhibitors 
[61]:  
 
   
(     
   
 
)
(
   
  
  )
⁄   (1) 
 
E is the active enzyme concentration (50 nM), [S] is the substrate concentration (50 µM) and 
IC50 is the concentration of inhibitor which results in half-maximal activity of the PR. IC50 values 
were determined using inhibitor concentrations ranging 0–200 µM. For all kinetic measurements, 
an excitation wavelength of 337 nm and emission wavelength of 425 nm were used for the 30 
second measurements during steady-state. Activity assays were performed in 50 mM sodium 
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 acetate and 1 M sodium chloride (pH 5.0) at 20 °C. For kcat/KM determinations, 0.1 M sodium 
chloride was used to obtain measurable rates of substrate cleavage. A final dimethyl sulfoxide 
concentration of 2% was used during IC50 determinations to ensure inhibitor solubility. All 
kinetic experiments were performed in triplicate using a Jasco FP-6300 spectrofluorometer and 
the data were fit using SigmaPlot (version 11.0). Kinetic parameters were used to calculate the 
relative vitality of the C-SA PR in the presence of PIs and compared to the subtype B PR 
according to the following equation [62]: 
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Displacement titration ITC 
 
Binding thermodynamics of atazanavir, darunavir and ritonavir binding to the C-SA PR were 
determined using a displacement titration method [63]. PIs were titrated into the sample cell 
containing the C-SA PR pre-bound to acetyl-pepstatin (200 µM final concentration). 
Thermodynamic parameters of C-SA PR binding were measured following titration of 150 µM 
atazanavir into 13.89 µM PR, 100 µM darunavir into 13.78 µM PR and 100 µM ritonavir into 
12.66 µM PR. For subtype B PR binding, 100 µM of ritonavir was titrated into 11.86 µM PR. 
Displacement titrations were performed in 10 mM sodium acetate and 2% dimethyl sulfoxide 
(pH 5.0) at 20 °C using a VP-ITC microcalorimeter (MicroCal Inc.). 
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 Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) 
 
The dynamics of the subtype B and C-SA PRs were investigated by HDX-MS as previously 
described [64-66]. For exchange experiments, 10 µl of PR stock solutions (1.3 mg/ml) were 
diluted 4-fold in 100% D2O at 20 °C. At appropriate time intervals, hydrogen-deuterium 
exchange (HDX) was minimised with a 1:1 dilution in 4 M guanidine hydrochloride and 1% 
formic acid (pH 2.3) and incubated on ice for 30 seconds. The PRs were fragmented with the 
addition of 13 µl of pepsin (1 µg/µl) and kept on ice for 5 minutes, resulting in a 1:1 (pepsin:PR) 
ratio. Following fragmentation, 50 µl of the PR solution was injected onto an Aeris PEPTIDE 
3.6 µm XB-C18 reversed-phase column (Phenomenex); submerged in ice; coupled to an AB 
SCIEX QSTAR
®
 Elite mass spectrometer via a 6-port switching valve. Peptides were eluted at 
300 μl/min from the reversed-phase column with a 5–95% B gradient in 10 minutes (A: 0.1 % 
formic acid; B: acetonitrile/0.1 % formic acid). Initial peptide identification was carried out 
using Collision Induced Dissociation (CID) in Information Dependent Acquisition (IDA) mode. 
All subsequent samples, including the non-deuterated and fully-deuterated, were analysed in MS 
mode. PR stock solutions were maintained in the standard storage buffer comprising 10 mM 
sodium acetate, 2 mM dithiothreitol and 0.02% sodium azide (pH 5.0). All experiments were 
performed in duplicate and data collection for each PR subtype was completed within 2 days.  
 
Undeuterated controls were analysed using PEAKS 6 (Bioinformatics Solutions Inc., Ontario, 
Canada; http://www.bioinfor.com) to determine the peptide coverage and peptide pool for HDX 
analysis. The percentage back-exchange that occurs once the HDX reaction is quenched (during 
fragmentation, peptide separation and mass spectrometry analysis) was determined using a fully-
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 deuterated control. On average, the percentage back-exchange for subtype B PR experiments was 
20.75% and 22.30% for C-SA PR experiments. HDX analysis was performed using 
HDExaminer 1.2 (Sierra Analytics Inc., California, USA; http://www.masspec.com). Manual 
quality control was performed on analysed peptides (high and medium confidence peptides only) 
to ensure that theoretical and experimental isotopic profiles matched. Deuterium incorporation 
versus exchange time was fit using SigmaPlot (version 11.0) according to the following equation 
[65]: 
 
     ∑          
 
   (3) 
 
were D is the deuterium content of a peptide, N is the number of peptide amide protons, ki is the 
exchange rate constant for each peptide amide proton and t is the time allowed for isotopic 
exchange. The total number of exponential terms (either one or two in this study) was selected 
based on the goodness of each fit. Structural images were constructed using the PyMOL 
Molecular Graphics System (Schrödinger LLC., Portland, USA; http://www.schrodinger.com).  
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 Table 1: Enzymatic parameters of the subtype B and C-SA PRs. 
HIV-1 Subtype KM (µM) kcat (s
-1
) kcat/KM (M
-1
s
-1
) 
B 38.7±6.0 9.0±0.2 3.2 × 10
-7
±0.1 × 10
-7
 
C-SA 29.4±4.4 20.6±0.8 4.6 × 10
-7
±0.5 × 10
-7
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 Table 2: Comparison of inhibitor binding between the subtype B and C-SA PRs. 
HIV-1 
Subtype 
ΔH 
(kcal/mol) 
-TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
Kd (nM) Ki (nM) Ki/Ki(B) Relative 
vitality 
Acetyl-pepstatin 
B 11.5 -20.2 -8.7 300    
C-SA 9.1 -17.9 -8.8 252    
Ritonavir 
B 3.0 -16.8 -13.8 0.049 6.47±2.17 1 1 
C-SA 2.0 -15.5 -13.5 0.083 18.25±1.72 2.82 4.05 
Atazanavir 
B -4.2 
a
 -10.1 
a
 -14.3 
a
 0.035 
a
 10.96±4.29 1 1 
C-SA -4.8 -9.2 -14.0 0.036 5.53±1.88 0.50 0.72 
Darunavir 
B -12.1 
b
 -3.1 
b
 -15.0 
b
 0.005 
b
 0.49±0.20 1 1 
C-SA -19.1 4.5 -14.6 0.012 3.30±1.42 6.73 9.67 
 
a
 Values cited from reference [20].
 
b
 Values cited from reference [19]. 
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 Table 3: Number of very fast, fast, intermediate and slow exchanging amide protons in 
peptides derived from the subtype B and C-SA PRs. 
HIV-1 
Subtype 
Peptide Very fast 
a
 
(ND) 
Fast  
(12>k >0.1 min
-1
) 
Intermediate  
(0.1>k>0.01 min
-1
) 
Slow 
b
        
(ND) 
B 
13–23 
1.7 0.9 2.5 3.9 
C-SA 1.4 - 3.4 4.2 
B 
34–53 
3.5 3.8 3.7 5.0 
C-SA 1.8 4.0 5.4 4.8 
B 
47–53 
1.3 1.5 0.7 1.5 
C-SA 0.8 1.2 1.2 1.8 
B 
64–76 
1.2 0.4 1.7 7.7 
C-SA 1.1 - 2.3 7.6 
B 
64–90 
1.2 1.8 3.3 16.7 
C-SA 1.2 - 5.2 16.6 
 
a 
Determined by subtracting the number of fast and intermediate exchanging amide protons from 
the total exchanged at 1 hour of incubation. 
b
 Determined by subtracting the total protons exchanged at 1 hour of incubation from the total 
amide protons available in the peptide. 
Rates are displayed in parenthesis. ND =
 
Not determined. 
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 Table 4: Number of amide protons exchanged at the N- and C-termini of the subtype B and 
C-SA PRs at 1 hour of deuterium oxide incubation. 
HIV-1 Subtype Peptide  Residues analysed 
a
 Number of protons exchanged 
B 
1–5  3–5 
1.74±0.04 
C-SA 1.60±0.04 
B 
77–94  79–94 
5.84±0.31 
C-SA 3.83±0.05 
B 
77–99  79–99 
7.17±0.22 
C-SA 7.79±0.05 
B Difference of 77–
99 and 77–94  
95–99 1.33±0.09 
C-SA 2.97±0.08 
B 
95–99  97–99 
0.77±0.05 
C-SA 0.91±0.03 
 
a
 Residues analysed exclude the first two amino acids of the peptide. 
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 Figure 1: Polymorphic sites of the subtype B and C-SA PRs. The flexible flaps of PR (residues at 
positions 46–54) are coloured cyan. The fulcrum (residues at positions 10–23), hinge (residues at 
positions 35–42 and 57–61) and cantilever (residues at positions 62–78) regions are implicated in 
flap opening. Locations of the eight polymorphic amino acids in each monomer are shown as 
spheres. The complete sequence alignment is displayed below the structure. The corresponding 
secondary structure is shown below the sequence. Arrows represent β-strands and waves 
represent α-helices. The sequence alignment was performed using Clustal X 2.0 [67, 68]. PDB 
ID: 3U71 [6].  
 
Figure 2: Overview of flap conformers displayed by the HIV-1 PR. The closed (A), semi-open 
(B) and fully-open (C) conformers are in dynamic equilibrium. Above the respective three-
dimensional structures are the top views of the conformers. The semi-open flap conformation is 
the most prevalent conformer in the absence of inhibitor. Crystal structure data is unavailable for 
a fully-open conformer which is characterised by upward and outward displacement of the flaps. 
Representation of the flap positioning of the fully-open conformer is based on MD simulation 
models [10]. 
 
Figure 3: Heat maps for amide hydrogen/deuterium exchange of the subtype B and C-SA PRs. 
The heat maps depict the percentage deuteration for all time points measured (10 s, 20 s, 30 s, 1 
min, 5 min, 20 min and 1 hr) at different regions of the PRs corresponding to the sequence 
above. Peptides which were detected and used for data processing are shown above the 
sequences. Positions of the polymorphisms are shown in red. The heat map shows the averaged 
deuteration for both monomers in the homodimeric PRs.  
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 Figure 4: Amide hydrogen/deuterium exchange kinetics of different regions of the PRs. (A) The 
corresponding positions of measured peptides are coloured blue on the structure. Graphs show 
the deuterium incorporation plots for: peptide 13–23, peptide 34–53 and peptide 64–90. (B) 
Deuterium incorporation plot of peptide 47–53 covering the flap tips of the PRs. 
 
Figure 5: Interactions localised around residue position 36 of the hinge region. In the subtype B 
PR (A), M36 seemingly provides anchorage for E35 and stabilises the salt bridge between E35 
and R57. I36 in the C-SA PR (B) is implicated in less hinge region interactions and disruption of 
the E35-R57 salt bridge. PDB ID: 2PC0 (A) [13], 3U71 (B) [6].  
 
Figure 6: Hydrophobic core of HIV-1 PR in stereo view. Residues comprising the hydrophobic 
core are shown as sticks. Flap tips (residue positions 46–54) are coloured cyan. The hinge 
regions (residue positions 35–42 and 57–61) coloured pink and the cantilever region (residue 
positions 62–78) coloured blue anchor the flap tips.  
 
Figure 7: Interactions made by F99. F99 is central to the illustrated ‘lock-and-key’ motif and is 
essential for dimerization. 
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Chapter 5 
General discussion and conclusions 
 
5.1 C-SA PR displays increased substrate turnover and reduced drug 
susceptibility in comparison to the subtype B PR 
 
Steady-state kinetic parameters were determined following hydrolysis of the HIV-1 PR 
fluorogenic substrate (Abz-Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2) which mimics the 
capsid/p2 cleavage site in the Gag and Gag-Pol polyprotein precursors. The KM and kcat/KM 
values displayed by the subtype B and C-SA PRs are comparable. However, the C-SA PR 
displays a 2-fold increase in substrate turnover per second (higher kcat). This improved rate of 
substrate processing may stem from a 23% increase in the proportion of fully-open 
conformers evident in the C-SA PR population relative to that of the subtype B PR
54
. 
Importantly, structure-based calculations reveal that semi-open conformers do not permit the 
entry of substrate/inhibitor to the active site
73
. Entry of a substrate or inhibitor to the active 
site of the PR requires substantial movement of the flaps (~ 15 Å from their position in the 
closed conformer)
58
 and flap flexibility is a requirement for substrate binding and product 
release
74
. Therefore, only the fully-open conformer may allow a substrate/inhibitor access to 
the active site. An increased preference for the fully-open conformer may improve the rate 
substrate entry and/or product release, evidenced by the increase in kcat for the C-SA PR. 
Binding kinetics of FDA-approved PIs to the HIV PR measured by surface plasmon 
resonance (SPR) showed that the rate of inhibitor dissociation is far slower than the rate of 
inhibitor association
75
. The rate of inhibitor dissociation is greater in multi-drug resistant 
91
(MDR) PRs than for the wild-type; however, display similar rates of inhibitor binding
75
. 
Therefore, polymorphisms which improve the rate of inhibitor dissociation through increased 
propensity for more open conformers may also improve the rate of substrate release. The 
increased preference for the fully-open conformer must be a result of some altered dynamics 
in the C-SA PR. Alterations in the regions which facilitate flap movement are likely to 
explain the greater presence of fully-open conformers because no polymorphisms occur in the 
flap region which may directly affect flap flexibility
27; 76
.  
 
The C-SA PR displayed reduced drug susceptibility toward ritonavir and darunavir in 
comparison to the subtype B PR. The relative vitality, indicating the selective advantage of 
polymorphisms, of the C-SA PR relative to the subtype B PR in the presence of ritonavir and 
darunavir was 4-fold and 10-fold greater, respectively. The vitality of the C-SA PR in the 
presence of atazanavir is comparable to that of the subtype B PR. All the aforementioned 
inhibitors, which are recommended in current antiretroviral therapy guidelines, bound with a 
reduced entropic contribution to the C-SA PR in comparison to the subtype B PR and an 
unfavourable entropy change (-TΔS > 0) was observed during darunavir binding. The 
reduced entropic contributions are compensated by improved enthalpic contributions with no 
significant difference in the change in Gibbs free energy during inhibitor binding to either 
PR. Enthalpy-entropy compensation is thought to be mainly based on the weak interactions of 
the bulk solvent. The reduced entropic contribution during inhibitor binding to the C-SA PR 
may be due to increased order of the inhibitor and/or solvent molecules in the binding cavity. 
Retention of ordered solvent in the binding cavity results in increased hydrogen bonding with 
the PR and other structural water molecules. These bonds are stronger than the intermolecular 
forces in the bulk solvent. Therefore, such bonds result in an enhanced enthalpy change.  
92
Altogether, the reduced susceptibility of the C-SA PR toward ritonavir and darunavir also 
substantiates the classification of the M36I, L89M and I93L mutations, which are inherent to 
the C-SA PR, as secondary drug resistance mutations.   
 
5.2 Global structures of PRs are similar in their static states 
 
The alignment of the crystal structures of the consensus subtype B and C-SA PRs revealed no 
major structural differences between the PRs. Protein dynamics data suggest a difference in 
the equilibrium between flap conformers for the apo-C-SA PR relative to the apo-subtype B 
PR
54
. Although no structural differences in the flap region of the apo-PRs were identified, the 
overall dynamics of the PRs need to be investigated to elucidate the mechanism of reduced 
drug susceptibility displayed by the C-SA PR. The polymorphic sites were investigated in 
detail and only structural differences at the polymorphic residue at position 36 were 
identified. The M36I polymorphism may hinder formation of the nearby E35-R57 salt bridge 
which is the only salt bridge in the flap-hinge region. The reduced propensity of the C-SA PR 
to form the E35-R57 salt bridge may facilitate altered anchoring of the flap-hinge region.  
 
The C-SA PR crystallised in the semi-open conformation with flaps displaying normal 
handedness (similar to the closed conformation Figure 5A). The flap tips (residue positions 
48–52) are displaced further away and do not overlap in contrast to the closed conformation. 
Two distinct types of semi-open conformers have been identified experimentally in crystal 
structures of the apo-HIV-1 PR
55
. The conventional semi-open conformer trapped during 
protein crystallography exhibits a reversal of flap handedness (Figure 5B). This conventional 
conformer appears to display slight flap tip curling similar to the curled and fully-open 
93
conformers (Figure 5C). However, both ensembles of the semi-open conformer may exist in 
solution. 
 
Previous drug-complexed structures of a subtype C PR with a sequence matching a patient 
from India displayed the same overall fold and no major structural differences to drug-
complexed subtype B PR structures
49
. A detailed analysis was possible using the indinavir 
bound structure of the subtype C PR which showed no significant difference in the number of 
hydrophobic interactions and hydrogen bonds between the drug and active site in comparison 
to the indinavir bound structure of the subtype B PR
49
. This subtype C PR did exhibit an 
increased proportion of the fully-open conformer in the apo-form in comparison to the 
subtype B PR
54
; however, any structural difference that may allow for the shift in the 
equilibrium of PR conformers was not identified in the crystal structures of the subtype C 
PR
49
. The aforementioned subtype C PR exhibits the N37A and K41R polymorphisms in 
comparison to the C-SA PR. Unfortunately, several attempts to obtain high-resolution drug-
complexed structures of the C-SA PR in the current study proved unsuccessful. Obtaining 
such structures is an objective of upcoming projects in our lab.   
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5.3 Isotope exchange mechanism of HIV-1 PR 
 
Hydrogen/deuterium exchange (HDX) under conditions where proteins are generally folded 
may be illustrated using a two-process model (Figure 6)
77-79
. Exchange in a folded protein 
(Figure 6A) is believed to occur through low amplitude atomic motions, of ~ 1 Å, which are 
sufficient to allow diffusion of D2O and OD
-
 to backbone amide linkages
80; 81
. The motion of 
a single atom is not large enough to allow penetration of solvent molecules; however, the 
collective effect of many independent motions occasionally allows for transient penetration 
of solvent
82
. Simultaneously, short segments as well as the entire protein backbone may 
exchange through unfolding processes
83
.  
 
HDX in macromolecules resulting from local unfolding events (Figure 6B) may either occur 
via a correlated (EX1) or uncorrelated (EX2) mechanism
82; 84-86
. Correlated HDX (EX1) 
occurs when the rate of isotopic exchange (kint) far exceeds the rate of refolding (k-1); and 
thus, all amide hydrogens within a segment exchange for deuterons in solution when the 
segment is unfolded
82; 84; 85
. HDX in the subtype B and C-SA PRs displays EX2 kinetics 
indicated by the single binomial isotopic distribution of the mass spectra in the current 
study
87
. This uncorrelated exchange mechanism may be well-illustrated by HDX at α-
helices
88. Exchange at residues in the single α-helix of the HIV-1 PR (residues at positions 
87–93) occurs independently of each other. HDX via the EX2 mechanism occurs when the 
rate of refolding (k-1) far exceeds the rate of isotopic exchange (kint), suggesting that segments 
of the PRs must unfold and refold many times before exchange within it is complete
82; 84; 85
. 
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 Figure 6: Description of isotope exchange in the folded (A) and unfolded (B) states of a 
protein. NH* denotes a backbone amide which has exchanged its proton with a deuterium 
atom in solution. H and D refer to hydrogen and deuterium, respectively, and f and u refer to 
the folded and unfolded forms. The isotopic exchange rate constant from the folded state is 
designated as kex,f. The unfolding rate (k1), refolding rate (k-1) and isotopic exchange rate (kint) 
constants are also displayed. 
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5.4 Conformational stability of HIV-1 PR 
 
Previous differential scanning calorimetry studies showed that the overall conformational 
stability of the C-SA PR was slightly reduced in comparison to the subtype B PR
16
. 
Hydrogen/deuterium exchange-mass spectrometry (HDX-MS) data reported in the current 
study identified subtle differences in stability at different regions of the PRs. In most 
peptides, the number of amide protons exchanging at fast rates increased by ~ 1 amide proton 
in the subtype B PR relative to the C-SA PR. This may initially imply that the C-SA PR is 
more stable than the subtype B PR. However, residues at the C-terminus (C95 and T96) of 
the C-SA PR appear to be more dynamic. Thermodynamic analyses showed that the N- and 
C-terminal antiparallel β-sheet contributes 75% to the total Gibbs energy89. A more dynamic 
C-terminus will affect the stability of the terminal β-sheet and greatly impact the overall 
conformational stability. Salt bridges also affect the conformational stability of 
macromolecules
90; 91
. Crystal structure analysis shows that the C-SA PR lacks the K20-E34 
and E35-R57 salt bridges relative to the subtype B PR. Therefore, the reduced number of 
ionic interactions and a less stable terminal β-sheet evident in the C-SA PR are major 
determinants for the apparent overall reduced conformational stability of the C-SA PR.  
 
 
5.5 Effect of polymorphisms on C-SA PR stability 
 
HDX-MS results indicate that the regions at the polymorphic sites of the C-SA PR are more 
stable than that of the subtype B PR. In all peptides covering the polymorphic sites (10’s, 
60’s and 80’s loops and the hinge region) there is a reduction in the number of very fast 
97
and/or fast exchanging amide protons (12 > k > 0.1 min
-1
) and a concomitant increase in the 
number of intermediate exchanging amide protons (0.1 > k > 0.01 min
-1
) in the C-SA PR. The 
differences observed in peptide 13–23 (covering the fulcrum region), 34–53 (covering the 
hinge region) and 64–76 (covering the cantilever region) may contribute to the varying 
preference of flap conformations between the PRs. Distance measurements during pulsed 
EPR experiments showed that the total population of the fully-open conformer increased by 
23% with a concomitant decrease by 15% in the total population of semi-open conformers in 
the subtype C PR relative to the subtype B PR. Complete flap opening occurs through 
concerted downward movement of the hinge (residue positions 35–42 and 57–61), cantilever 
(residue positions 62–78) and fulcrum (residue positions 10–23) regions and the exchange of 
hydrophobic contacts between these regions
92
. In the C-SA PR, I15V, L19I, M36I, L89M and 
I93L polymorphisms occur in the hydrophobic core. These polymorphisms may alter the 
network of hydrophobic contacts in the core. It is evident from the crystal structures of the 
apo-subtype B and C-SA PRs that these polymorphisms bring about slight changes in the 
complex network of hydrophobic interactions. Due to its high incidence in drug-resistant 
isolates, the M36I polymorphism likely contributes the greatest to differences in flap 
dynamics between the PRs. The rotation of I36 through different rotamers may assist in 
sliding over other hydrophobic residues. In addition, the reduced propensity of the C-SA PR 
to form the E35-R57 salt bridge may aid in the sliding of hydrophobic residues in the core 
and not reduce stability in the hinge region as initially predicted
27
. HDX-MS data indicate 
that the network of interactions in the hydrophobic core of the C-SA PR may be altered. 
Segments of the hinge, cantilever and fulcrum regions display increased stability in the C-SA 
PR which may ultimately stabilise the fully-open conformer. 
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5.6 C-SA PR displays a wider range of fully-open conformers 
 
MD simulations were performed to identify differences in flap tip dynamics between the 
subtype B and C-SA PRs. The inter-flap distances (distance between Cα of I50 on adjacent 
monomers) of the PRs were measured to probe flap tip dynamics over 10 nanoseconds. NMR 
studies have indicated that motion of the flap tips do occur on a time-scale of less than 10 
nanoseconds
51
. Simulations were also performed on a PR from a multi-drug resistant clinical 
isolate (MDR 769)
93
. All PR structures used for simulations displayed normal flap 
handedness and this simulation study probed movements of the flap tip of this type of semi-
open conformer in the PRs. The MDR PR displayed drug resistance to most FDA-approved 
PIs and reduced susceptibility to the second generation PIs; namely, darunavir, lopinavir and 
tipranavir
94
. The MDR PR was expected to show a difference in flap dynamics due the 
presence of flap region mutations (M46L and I54V). A wider displaced semi-open 
conformation was displayed by the MDR PR for ~ 4 nanoseconds of the 10 nanosecond 
simulation. However, spin-labelled pulsed EPR spectroscopy studies did not reveal a wider 
semi-open conformer for the MDR PR. A wider fully-open conformer was rather identified
54; 
95
. It is important to note the type of starting structure used during the simulation of the 
current study. The PRs in the wide semi-open conformation (Figure 7C), displaying normal 
flap handedness, used in the current study has been likened to a wide-open conformer
47; 55
. 
Although this type of semi-open conformer does not display a reversal of flap handedness, as 
seen in conventional semi-open conformers (Figure 7B) and simulations of the fully-open 
conformer
57
, the distance between the flap tips is far greater than that displayed by the 
conventional semi-open conformer and is likened to the wider opening displayed by the fully-
open conformer
55
. Therefore, flap tip dynamics reported here may be indicative of the type of 
motions which occur when the flaps are displaced further apart, as in the fully-open 
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conformer, rather than close together as displayed by the conventional semi-open 
conformer
55
. Large-scale flap motions indicative of full flap opening occur on the 
microsecond–millisecond time-scale51. Sampling fully-open flap conformers via MD 
simulations on a computationally feasible time-scale has only been possible using a 
continuum solvent representation with reduced viscosity, allowing for accelerated protein 
motions
57; 96
. These studies were performed using a closed (Figure 7A) and a conventional 
semi-open conformer (Figure 7B)
57
. Whether the wide semi-open conformer is 
physiologically relevant is up for debate. However, it does exhibit some characteristics of the 
fully-open conformer. 
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 Figure 7: Inter-flap distances of closed and semi-open conformers. Inter-flap distances in 
red are based on crystal structure data. The wide semi-open conformers of the subtype B and 
C-SA PRs relax to ~ 7 Å during the simulation experiment in this study. PDB ID: 1HXW 
(A)
61
, 1HHP (B)
62
 and 2PC0 (C)
55
. 
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The C-SA PR does not display larger inter-flap distances in comparison to the subtype B PR. 
Following complete equilibration of all PR starting structures (after ~ 3.8 nanoseconds), the 
PRs relax to either the closed or the wide semi-open conformer which displays closer inter-
flap distances (~ 7 Å) than that of the respective crystal structures. The subtype B and C-SA 
PRs displayed “closed” inter-flap distances (~ 5.8 Å) for part of the simulation and exhibited 
inter-flap distances indicative of the wider semi-open conformation at the end of the 
simulation. However, the range of inter-flap distances following equilibration of both 
structures is wider for the subtype C PR. These results are consistent with pulsed EPR 
spectroscopy experiments which showed a wider range of fully-open conformers for the C-
SA PR in comparison to the subtype B PR
54
. The range of semi-open conformers were 
similar
54
, consistent with the notion that differences in inter-flap distance measured in the 
present simulation report on the motion of open flaps. This difference was highlighted by a 
broader peak width at half maximal intensity for the fully-open population of the C-SA PR 
during pulsed EPR spectroscopy measurements
54
. These results together with that reported in 
the current study indicate that the C-SA PR must display altered dynamics to allow for the 
stabilisation of the wider range of open conformers. It is improbable that the wider range of 
open conformers is due to altered dynamics at the flap tips because no polymorphisms are 
located in the flap region. HDX-MS results reported in the current study did not show 
increased dynamics at the flap tips of the C-SA PR. Our results suggest that altered dynamics 
around the flaps and the increased propensity for fully-open conformations is a result of 
altered dynamics in the regions which allow for flap opening and closure.  
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5.7 Key features of dimerisation in HIV-1 PRs 
 
The N-terminus (positions 1–5) and C-terminus (positions 95–99) of HIV-1 PRs are pivotal 
in dimer stability; structure-based thermodynamic analyses showed that the N- and C-termini 
antiparallel β-sheet contributes ~ 75% to the total Gibbs energy89. HDX-MS data reveal that 
the N-terminus of both PRs is more flexible than the C-terminus, supporting previous 
structural analysis. These findings further substantiate the ordered initial cleavage of the 
p6
Pol
-PR junction prior to cleavage of the more stable PR-RT junction
97
.  
 
Drug resistance to currently available PIs are attributed to mutations in the active site cavity 
and flap-hinge region. Dimerisation inhibitors targeted to the conserved C-terminus of HIV 
PR may have a higher barrier to resistance. The C-terminal residues, C95 and T96, are more 
dynamic in the C-SA PR in comparison to that of the subtype B PR. Therefore, these residues 
may contribute less to the stability of the N- and C-termini β-sheet than other C-terminal 
residues and may not serve as suitable targets for preventing dimerisation. Mutation of the 
ultimate amino acid in the HIV-1 PR sequence, phenylalanine, to an alanine was shown to 
reduce the β-sheet content of the PR and disrupt dimerisation which results in complete loss 
of activity
98
. F99 is central to the large network of interactions present in the ‘lock-and-key’ 
motif. Therefore, the importance of the C-terminus for correct folding of the PR and its 
increased stability in comparison to the N-terminus, make the C-terminus, particularly F99, a 
preferred target for antiviral therapy. 
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5.8 Conclusions 
 
Polymorphisms inherent in the C-SA PR represent non-active site and non-flap region 
mutations. These polymorphisms result in the C-SA PR displaying improved viral fitness in 
the presence of certain PIs in comparison to the subtype B PR. The improved viral fitness is 
not explained by the static structure of the C-SA PR which is comparable to that of the 
subtype B PR. Previous and current investigations of flap dynamics indicate that the C-SA 
PR has an increased preference for the fully-open conformer and polymorphisms inherent in 
the C-SA PR allow for a wider range of these fully-open conformers
27; 54
. Increased stability 
in segments of the hinge, cantilever and fulcrum regions likely allow for altered anchoring of 
the flaps ultimately increasing the preference of fully-open conformers in the C-SA PR in 
comparison to the subtype B PR. Because the C-SA PR displays reduced drug susceptibility 
and similar catalytic efficiency in comparison to the subtype B PR, selection of fully-open 
conformers preferentially affects inhibitor binding over substrate binding. FDA-approved PIs 
were designed to target the closed conformation of the PR and are more rigid than substrates 
of HIV PR. As substrate processing is more dynamic than inhibitor binding, polymorphisms 
which promote more open conformers do not hinder substrate processing; rather, they may 
improve substrate turnover as shown by the increase in kcat for the C-SA PR. Inhibitors 
designed to target the fully-open conformer of the PR, which is a prerequisite for substrate 
binding, may be preferred for PRs which have a preference for the fully-open conformer such 
as the epidemiologically relevant C-SA PR.   
 
 
104
References 
 
1. The Joint Nations Program on HIV/AIDS (UNAIDS). (2013). Global report: 
UNAIDS report on the global AIDS epidemic 2013, UNAIDS: Geneva, Switzerland. 
2. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., 
Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W. & 
Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk 
for acquired immune deficiency syndrome (AIDS). Science 220, 868-871. 
3. Bebenek, K., Abbotts, J., Roberts, J. D., Wilson, S. H. & Kunkel, T. A. (1989). 
Specificty and mechanism of error-prone replication by human immonodeficiency 
virus-1 reverse-transcriptase. J. Biol. Chem. 264, 16948-16956. 
4. Tomasselli, A. G. & Heinrikson, R. L. (2000). Targeting the HIV-protease in AIDS 
therapy: a current clinical perspective. Biochim. Biophys. Acta 1477, 189-214. 
5. de Oliveira, T., Engelbrecht, S., van Rensburg, E. J., Gordon, M., Bishop, K., zur 
Megede, J., Barnett, S. W. & Cassol, S. (2003). Variability at human 
immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of 
viral fitness? J. Virol. 77, 9422-9430. 
6. Naicker, P. & Sayed, Y. (2014). Non-B HIV-1 subtypes in sub-Saharan Africa: 
impact of subtype on protease inhibitor efficacy Biol. Chem., In Press. 
7. Monini, P., Sgadari, C., Toschi, E., Barillari, G. & Ensoli, B. (2004). Antitumour 
effects of antiretroviral therapy. Nat. Rev. Cancer 4, 861-875. 
8. McCutchan, F. E. (2006). Global epidemiology of HIV. J. Med. Virol. 78, 7-12. 
9. Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E. & Hammer, S. M. (2008). 
Medical progress: The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358, 
1590-1602. 
105
10. Plantier, J. C., Leoz, M., Dickerson, J. E., De Oliveira, F., Cordonnier, F., Lemee, V., 
Damond, F., Robertson, D. L. & Simon, F. (2009). A new human immunodeficiency 
virus derived from gorillas. Nat. Med. 15, 871-872. 
11. Hemelaar, J., Gouws, E., Ghys, P. D. & Osmanov, S. (2011). Global trends in 
molecular epidemiology of HIV-1 during 2000-2007. AIDS 25, 679-89. 
12. Clemente, J. C., Moose, R. E., Hemrajani, R., Whitford, L. R. S., Govindasamy, L., 
Reutzel, R., McKenna, R., Agbandje-McKenna, M., Goodenow, M. M. & Dunn, B. 
M. (2004). Comparing the accumulation of active- and nonactive-site mutations in the 
HIV-1 protease. Biochemistry 43, 12141-12151. 
13. King, N. M., Prabu-Jeyabalan, M., Bandaranayake, R. M., Nalam, M. N. L., 
Nalivaika, E. A., Ozen, A., Haliloglu, T., Yilmaz, N. K. & Schiffer, C. A. (2012). 
Extreme Entropy-Enthalpy Compensation in a Drug-Resistant Variant of HIV-1 
Protease. ACS Chem. Biol. 7, 1536-1546. 
14. Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., 
Schmelmer, V., Amzel, L. M. & Freire, E. (2007). Unique thermodynamic response 
of tipranavir to human immunodeficiency virus type 1 protease drug resistance 
mutations. J. Virol. 81, 5144-54. 
15. Velazquez-Campoy, A., Kiso, Y. & Freire, E. (2001). The binding energetics of first- 
and second-generation HIV-1 protease inhibitors: Implications for drug design. Arch. 
Biochem. Biophys. 390, 169-175. 
16. Velazquez-Campoy, A., Vega, S., Fleming, E., Bacha, U., Sayed, Y., Dirr, H.W. & 
Freire, E. (2003). Protease Inhibition in African Subtypes of HIV-1. AIDS Rev. 5, 
165-171. 
17. Hemelaar, J., Gouws, E., Ghys, P. D. & Osmanov, S. (2006). Global and regional 
distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, 13-23. 
106
18. Kantor, R. & Katzenstein, D. (2003). Polymorphism in HIV-1 Non-subtype B 
Protease and Reverse Transcriptase and its Potential Impact on Drug Susceptibility 
and Drug Resistance Evolution. AIDS Rev. 5, 25-35. 
19. Loeb, D. D., Hutchison, C. A., Edgell, M. H., Farmerie, W. G. & Swanstrom, R. 
(1989). Mutational  analysis of human immunodeficiency virus type-1 protease 
suggests functional homology with aspartic proteinases J. Virol. 63, 111-121. 
20. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, 
I. T., Selk, L. M., Clawson, L., Schneider, J. & Kent, S. B. H. (1989). Conserved 
folding in  retroviral proteases - crystal-structure of a synthetic HIV-1 protease. 
Science 245, 616-621. 
21. Wlodawer, A. & Vondrasek, J. (1998). Inhibitors of HIV-1 protease: A major success 
of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27, 249-284. 
22. Flexner, C. (1998). HIV-protease inhibitors. N. Engl. J. Med. 338, 1281-1292. 
23. Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., 
Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., Demeter, L. 
M., Vella, S., Jacobsen, D. M. & Richman, D. D. (2000). Antiretroviral drug 
resistance testing in adult HIV-1 infection - Recommendations of an International 
AIDS Society-USA panel. JAMA 283, 2417-2426. 
24. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., 
Schipper, P., Gulnik, S. & Boucher, C. A. (1999). Increased fitness of drug resistant 
HIV-1 protease as a result of acquisition of compensatory mutations during 
suboptimal therapy. AIDS 13, 2349-59. 
25. Rose, R. E., Gong, Y. F., Greytok, J. A., Bechtold, C. M., Terry, B. J., Robinson, B. 
S., Alam, M., Colonno, R. J. & Lin, P. F. (1996). Human immunodeficiency virus 
107
type 1 viral background plays a major role in development of resistance to protease 
inhibitors. Proc. Natl. Acad. Sci. U.S.A. 93, 1648-53. 
26. World Health Organisation (WHO). (2013). The use of antiretroviral drugs for 
treating and preventing HIV infection, Geneva, Switzerland: WHO Press. 
27. Naicker, P., Achilonu, I., Fanucchi, S., Fernandes, M., Ibrahim, M. A. A., Dirr, H. W., 
Soliman, M. E. S. & Sayed, Y. (2013). Structural insights into the South African HIV-
1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug 
resistance. J. Biomol. Struct. Dyn. 31, 1370-1380. 
28. Kozisek, M., Lepsik, M., Grantz Saskova, K., Brynda, J., Konvalinka, J. & Rezacova, 
P. (2014). Thermodynamic and structural analysis of HIV protease resistance to 
darunavir - analysis of heavily mutated patient-derived HIV-1 proteases. FEBS J. 281, 
1834-47. 
29. Ali, A., Bandaranayake, R. M., Cai, Y. F., King, N. M., Kolli, M., Mittal, S., 
Murzycki, J. F., Nalam, M. N. L., Nalivaika, E. A., Ozen, A., Prabu-Jeyabalan, M. 
M., Thayer, K. & Schiffer, C. A. (2010). Molecular Basis for Drug Resistance in 
HIV-1 Protease. Viruses 2, 2509-2535. 
30. Wiley, R. A. & Rich, D. H. (1993). Peptidomimetics derived from natural-products. 
Med. Res. Rev. 13, 327-384. 
31. Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, 
E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., 
Plattner, J. J., Norbeck, D. W. & Leonard, J. M. (1997). Pharmacokinetic 
enhancement of inhibitors of the human immunodeficiency virus protease by 
coadministration with ritonavir. Antimicrob. Agents Chemother. 41, 654-660. 
32. Altman, M. D., Ali, A., Reddy, G., Nalam, M. N. L., Anjum, S. G., Cao, H., 
Chellappan, S., Kairys, V., Fernandes, M. X., Gilson, M. K., Schiffer, C. A., Rana, T. 
108
M. & Tidor, B. (2008). HIV-1 protease inhibitors from inverse design in the substrate 
envelope exhibit subnanomolar binding to drug-resistant variants. J. Am. Chem. Soc. 
130, 6099-6113. 
33. Prabu-Jeyabalan, M., Nalivaika, E. & Schiffer, C. A. (2002). Substrate shape 
determines specificity of recognition for HIV-1 protease: Analysis of crystal 
structures of six substrate complexes. Structure 10, 369-381. 
34. Pokorna, J., Machala, L., Rezacova, P. & Konvalinka, J. (2009). Current and Novel 
Inhibitors of HIV Protease. Viruses 1, 1209-1239. 
35. Prabu-Jeyabalan, M., Nalivaika, E. & Schiffer, C. A. (2000). How does a symmetric 
dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. 
Mol. Biol. 301, 1207-1220. 
36. Cherry, E., Liang, C., Rong, L., Quan, Y., Inouye, P., Li, X., Morin, N., Kotler, M. & 
Wainberg, M. A. (1998). Characterization of human immunodeficiency virus type-1 
(HIV-1) particles that express protease-reverse transcriptase fusion proteins. J. Mol. 
Biol. 284, 43-56. 
37. Co, E., Koelsch, G., Lin, Y., Ido, E., Hartsuck, J. A. & Tang, J. (1994). Proteolytic 
processing mechanisms of a miniprecursor of the aspartic protease of human 
immunodeficiency virus type 1. Biochemistry 33, 1248-54. 
38. Louis, J. M., Clore, G. M. & Gronenborn, A. M. (1999). Autoprocessing of HIV-1 
protease is tightly coupled to protein folding. Nat. Struct. Biol. 6, 868-75. 
39. Louis, J. M., Nashed, N. T., Parris, K. D., Kimmel, A. R. & Jerina, D. M. (1994). 
Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 
protease from an analog of the Gag-Pol polyprotein. Proc. Natl. Acad. Sci. U.S.A. 91, 
7970-4. 
109
40. Wondrak, E. M., Nashed, N. T., Haber, M. T., Jerina, D. M. & Louis, J. M. (1996). A 
transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of 
maturation. J. Biol. Chem. 271, 4477-81. 
41. Hyland, L. J., Tomaszek, T. A., Jr., Roberts, G. D., Carr, S. A., Magaard, V. W., 
Bryan, H. L., Fakhoury, S. A., Moore, M. L., Minnich, M. D., Culp, J. S., DesJarlais, 
R. L. & Meek, T. D. (1991). Human immunodeficiency virus-1 protease. 1. Initial 
velocity studies and kinetic characterization of reaction intermediates by 18O isotope 
exchange. Biochemistry 30, 8441-53. 
42. Shen, C. H., Tie, Y., Yu, X., Wang, Y. F., Kovalevsky, A. Y., Harrison, R. W. & 
Weber, I. T. (2012). Capturing the reaction pathway in near-atomic-resolution crystal 
structures of HIV-1 protease. Biochemistry 51, 7726-32. 
43. Hyland, L. J., Tomaszek, T. A., Jr. & Meek, T. D. (1991). Human immunodeficiency 
virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to 
elucidate details of chemical mechanism. Biochemistry 30, 8454-63. 
44. Smith, R., Brereton, I. M., Chai, R. Y. & Kent, S. B. (1996). Ionization states of the 
catalytic residues in HIV-1 protease. Nat. Struct. Biol. 3, 946-50. 
45. Wang, Y. X., Freedberg, D. I., Yamazaki, T., Wingfield, P. T., Stahl, S. J., Kaufman, 
J. D., Kiso, Y. & Torchia, D. A. (1996). Solution NMR evidence that the HIV-1 
protease catalytic aspartyl groups have different ionization states in the complex 
formed with the asymmetric drug KNI-272. Biochemistry 35, 9945-50. 
46. Coman, R. M., Robbins, A., Goodenow, M. M., McKenna, R. & Dunn, B. M. (2007). 
Expression, purification and preliminary X-ray crystallographic studies of the human 
immunodeficiency virus 1 subtype C protease. Acta Crystallogr. F 63, 320-323. 
47. Coman, R. M., Robbins, A. H., Goodenow, M. M., Dunn, B. M. & McKenna, R. 
(2008). High-resolution structure of unbound human immunodeficiency virus 1 
110
subtype C protease: implications of flap dynamics and drug resistance. Acta 
Crystallogr. D 64, 754-763. 
48. Velazquez-Campoy, A., Vega, S. & Freire, E. (2002). Amplification of the effects of 
drug resistance mutations by background polymorphisms in HIV-1 protease from 
African subtypes. Biochemistry 41, 8613-9. 
49. Coman, R. M., Robbins, A. H., Fernandez, M. A., Gilliland, C. T., Sochet, A. A., 
Goodenow, M. M., McKenna, R. & Dunn, B. M. (2008). The contribution of naturally 
occurring polymorphisms in altering the biochemical and structural characteristics of 
HIV-1 subtype C protease. Biochemistry 47, 731-43. 
50. Freedberg, D. I., Ishima, R., Jacob, J., Wang, Y. X., Kustanovich, I., Louis, J. M. & 
Torchia, D. A. (2002). Rapid structural fluctuations of the free HIV protease flaps in 
solution: relationship to crystal structures and comparison with predictions of 
dynamics calculations. Protein Sci. 11, 221-32. 
51. Ishima, R., Freedberg, D. I., Wang, Y. X., Louis, J. M. & Torchia, D. A. (1999). Flap 
opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, 
and their implications for function. Structure 7, 1047-55. 
52. Nicholson, L. K., Yamazaki, T., Torchia, D. A., Grzesiek, S., Bax, A., Stahl, S. J., 
Kaufman, J. D., Wingfield, P. T., Lam, P. Y., Jadhav, P. K. & et al. (1995). Flexibility 
and function in HIV-1 protease. Nat. Struct. Biol. 2, 274-80. 
53. Galiano, L., Bonora, M. & Fanucci, G. E. (2007). Interflap distances in HIV-1 
protease determined by pulsed EPR measurements. J. Am. Chem. Soc. 129, 11004-5. 
54. Kear, J. L., Blackburn, M. E., Veloro, A. M., Dunn, B. M. & Fanucci, G. E. (2009). 
Subtype polymorphisms among HIV-1 protease variants confer altered flap 
conformations and flexibility. J. Am. Chem. Soc. 131, 14650-1. 
111
55. Heaslet, H., Rosenfeld, R., Giffin, M., Lin, Y. C., Tam, K., Torbett, B. E., Elder, J. H., 
McRee, D. E. & Stout, C. D. (2007). Conformational flexibility in the flap domains of 
ligand-free HIV protease. Acta Crystallogr. D 63, 866-875. 
56. Scott, W. R. & Schiffer, C. A. (2000). Curling of flap tips in HIV-1 protease as a 
mechanism for substrate entry and tolerance of drug resistance. Structure 8, 1259-65. 
57. Hornak, V., Okur, A., Rizzo, R. C. & Simmerling, C. (2006). HIV-1 protease flaps 
spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. 
Sci. U.S.A. 103, 915-20. 
58. Gustchina, A. & Weber, I. T. (1990). Comparison of inhibitor binding in HIV-1 
protease and in non-viral aspartic proteases: the role of the flap. FEBS Lett. 269, 269-
72. 
59. Huang, X., de Vera, I. M., Veloro, A. M., Blackburn, M. E., Kear, J. L., Carter, J. D., 
Rocca, J. R., Simmerling, C., Dunn, B. M. & Fanucci, G. E. (2012). Inhibitor-induced 
conformational shifts and ligand-exchange dynamics for HIV-1 protease measured by 
pulsed EPR and NMR spectroscopy. J. Phys. Chem. B 116, 14235-44. 
60. Martin, P., Vickrey, J. F., Proteasa, G., Jimenez, Y. L., Wawrzak, Z., Winters, M. A., 
Merigan, T. C. & Kovari, L. C. (2005). "Wide-open" 1.3 A structure of a multidrug-
resistant HIV-1 protease as a drug target. Structure 13, 1887-95. 
61. Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, 
C. A., Green, B. E., Fino, L., Park, C. H., Kong, X. P. & et al. (1995). ABT-538 is a 
potent inhibitor of human immunodeficiency virus protease and has high oral 
bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 92, 2484-8. 
62. Spinelli, S., Liu, Q. Z., Alzari, P. M., Hirel, P. H. & Poljak, R. J. (1991). The three-
dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 
73, 1391-6. 
112
63. Agniswamy, J., Shen, C. H., Aniana, A., Sayer, J. M., Louis, J. M. & Weber, I. T. 
(2012). HIV-1 protease with 20 mutations exhibits extreme resistance to clinical 
inhibitors through coordinated structural rearrangements. Biochemistry 51, 2819-28. 
64. Braz, V. A., Barkley, M. D., Jockusch, R. A. & Wintrode, P. L. (2010). Efavirenz 
Binding Site in HIV-1 Reverse Transcriptase Monomers. Biochemistry 49, 10565-
10573. 
65. Lanman, J., Lam, T. T., Barnes, S., Sakalian, M., Emmett, M. R., Marshall, A. G. & 
Prevelige, P. E. (2003). Identification of novel interactions in HIV-1 capsid protein 
assembly by high-resolution mass spectrometry. J. Mol. Biol. 325, 759-772. 
66. Lanman, J., Lam, T. T., Emmett, M. R., Marshall, A. G., Sakalian, M. & Prevelige, P. 
E. (2004). Key interactions in HIV-1 maturation identified by hydrogen-deuterium 
exchange. Nat. Struct. Mol. Biol. 11, 676-677. 
67. Monroe, E. B., Kang, S., Kyere, S. K., Li, R. & Prevelige, P. E. (2010). 
Hydrogen/Deuterium Exchange Analysis of HIV-1 Capsid Assembly and Maturation. 
Structure 18, 1483-1491. 
68. Descamps, D., Chaix, M. L., Andre, P., Brodard, V., Cottalorda, J., Deveau, C., 
Harzic, M., Ingrand, D., Izopet, J., Kohli, E., Masquelier, B., Mouajjah, S., Palmer, P., 
Pellegrin, I., Plantier, J. C., Poggi, C., Rogez, S., Ruffault, A., Schneider, V., Signori-
Schmuck, A., Tamalet, C., Wirden, M., Rouzioux, C., Brun-Vezinet, F., Meyer, L. & 
Costagliola, D. (2005). French national sentinel survey of antiretroviral drug 
resistance in patients with HIV-1 primary infection and in antiretroviral-naive 
chronically infected patients in 2001-2002. J. Acquir. Immune. Defic. Syndr. 38, 545-
52. 
69. Foster, G. M., Ambrose, J. C., Hue, S., Delpech, V. C., Fearnhill, E., Abecasis, A. B., 
Leigh Brown, A. J. & Geretti, A. M. (2014). Novel HIV-1 Recombinants Spreading 
113
across Multiple Risk Groups in the United Kingdom: The Identification and 
Phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One 9, 
e83337. 
70. Holguin, A., de Mulder, M., Yebra, G., Lopez, M. & Soriano, V. (2008). Increase of 
non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards 
and immigrants in Spain. Curr. HIV Res. 6, 327-34. 
71. Kanizsai, S., Ghidan, A., Ujhelyi, E., Banhegyi, D. & Nagy, K. (2010). Monitoring of 
drug resistance in therapy-naive HIV infected patients and detection of African HIV 
subtypes in Hungary. Acta Microbiol. Immunol. Hung. 57, 55-68. 
72. Mendoza, Y., Bello, G., Castillo Mewa, J., Martinez, A. A., Gonzalez, C., Garcia-
Morales, C., Avila-Rios, S., Reyes-Teran, G. & Pascale, J. M. (2014). Molecular 
Epidemiology of HIV-1 in Panama: Origin of Non-B Subtypes in Samples Collected 
from 2007 to 2013. PLoS One 9, e85153. 
73. Rick, S. W., Erickson, J. W. & Burt, S. K. (1998). Reaction path and free energy 
calculations of the transition between alternate conformations of HIV-1 protease. 
Proteins 32, 7-16. 
74. Tozser, J., Yin, F. H., Cheng, Y. S., Bagossi, P., Weber, I. T., Harrison, R. W. & 
Oroszlan, S. (1997). Activity of tethered human immunodeficiency virus 1 protease 
containing mutations in the flap region of one subunit. Eur. J. Biochem. 244, 235-41. 
75. Dierynck, I., De Wit, M., Gustin, E., Keuleers, I., Vandersmissen, J., Hallenberger, S. 
& Hertogs, K. (2007). Binding kinetics of darunavir to human immunodeficiency 
virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. 
Virol. 81, 13845-51. 
76. Piana, S., Carloni, P. & Rothlisberger, U. (2002). Drug resistance in HIV-1 protease: 
Flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11, 2393-402. 
114
77. Bai, Y., Milne, J. S., Mayne, L. & Englander, S. W. (1994). Protein stability 
parameters measured by hydrogen exchange. Proteins 20, 4-14. 
78. Kim, K. S. & Woodward, C. (1993). Protein internal flexibility and global stability: 
effect of urea on hydrogen exchange rates of bovine pancreatic trypsin inhibitor. 
Biochemistry 32, 9609-13. 
79. Li, R. & Woodward, C. (1999). The hydrogen exchange core and protein folding. 
Protein Sci. 8, 1571-90. 
80. Elber, R. & Karplus, M. (1987). Multiple conformational states of proteins: a 
molecular dynamics analysis of myoglobin. Science 235, 318-21. 
81. Kim, K. S., Fuchs, J. A. & Woodward, C. K. (1993). Hydrogen exchange identifies 
native-state motional domains important in protein folding. Biochemistry 32, 9600-
9608. 
82. Woodward, C., Simon, I. & Tuchsen, E. (1982). Hydrogen exchange and the dynamic 
structure of proteins. Mol. Cell. Biochem. 48, 135-60. 
83. Engen, J. R., Gmeiner, W. H., Smithgall, T. E. & Smith, D. L. (1999). Hydrogen 
exchange shows peptide binding stabilizes motions in Hck SH2. Biochemistry 38, 
8926-35. 
84. Englander, S. W. & Kallenbach, N. R. (1983). Hydrogen exchange and structural 
dynamics of proteins and nucleic acids. Q. Rev. Biophys. 16, 521-655. 
85. Roder, H., Wagner, G. & Wuthrich, K. (1985). Individual amide proton exchange 
rates in thermally unfolded basic pancreatic trypsin inhibitor. Biochemistry 24, 7407-
11. 
86. Englander, S. W., Downer, N. W. & Teitelbaum, H. (1972). Hydrogen exchange. 
Annu. Rev. Biochem. 41, 903-24. 
115
87. Miranker, A., Robinson, C. V., Radford, S. E., Aplin, R. T. & Dobson, C. M. (1993). 
Detection of transient protein folding populations by mass spectrometry. Science 262, 
896-900. 
88. Maity, H., Lim, W. K., Rumbley, J. N. & Englander, S. W. (2003). Protein hydrogen 
exchange mechanism: local fluctuations. Protein Sci. 12, 153-60. 
89. Todd, M. J., Semo, N. & Freire, E. (1998). The structural stability of the HIV-1 
protease. J. Mol. Biol. 283, 475-488. 
90. Fersht, A. R. (1972). Conformational equilibria in alpha and delta chymotrypsin. The 
energetics and importance of the salt bridge. J. Mol. Biol. 64, 497-509. 
91. Perutz, M. F. (1978). Electrostatic effects in proteins. Science 201, 1187-91. 
92. Foulkes-Murzycki, J. E., Scott, W. R. & Schiffer, C. A. (2007). Hydrophobic sliding: 
a possible mechanism for drug resistance in human immunodeficiency virus type 1 
protease. Structure 15, 225-33. 
93. Logsdon, B. C., Vickrey, J. F., Martin, P., Proteasa, G., Koepke, J. I., Terlecky, S. R., 
Wawrzak, Z., Winters, M. A., Merigan, T. C. & Kovari, L. C. (2004). Crystal 
structures of a multidrug-resistant human immunodeficiency virus type 1 protease 
reveal an expanded active-site cavity. J. Virol. 78, 3123-32. 
94. Wang, Y., Liu, Z. G., Brunzelle, J. S., Kovari, I. A., Dewdney, T. G., Reiter, S. J. & 
Kovari, L. C. (2011). The higher barrier of darunavir and tipranavir resistance for 
HIV-1 protease. Biochem. Biophys. Res. Commun. 412, 737-742. 
95. de Vera, I. M., Blackburn, M. E. & Fanucci, G. E. (2012). Correlating conformational 
shift induction with altered inhibitor potency in a multidrug resistant HIV-1 protease 
variant. Biochemistry 51, 7813-5. 
116
96. Ding, F., Layten, M. & Simmerling, C. (2008). Solution structure of HIV-1 protease 
flaps probed by comparison of molecular dynamics simulation ensembles and EPR 
experiments. J. Am. Chem. Soc. 130, 7184-5. 
97. Agniswamy, J., Sayer, J. M., Weber, I. T. & Louis, J. M. (2012). Terminal Interface 
Conformations Modulate Dimer Stability Prior to Amino Terminal Autoprocessing of 
HIV-1 Protease. Biochemistry 51, 1041-1050. 
98. Naicker, P., Seele, P., Dirr, H. W. & Sayed, Y. (2013). F99 is critical for dimerization 
and activation of South African HIV-1 subtype C protease. Protein J. 32, 560-567. 
 
  
117
